POLYMERICALLY COATED NANOCAPPSULES, PROCESS FOR THE PREPARATION OF POLYMERICALLY COATED NANOCAPPSULE

专利摘要:
nanocapsules containing miroemulsions delivery system based on polymeric nanocapsules that contain microemulsions and their use in the preparation of pharmaceutical, cosmetic and / or food compositions.
公开号:BR112013006269A2
申请号:R112013006269-0
申请日:2011-09-20
公开日:2020-05-26
发明作者:Lluis Viladot Petit Josep；Delgado Gonzalez Raquel；Fernandez Botello Alfonso
申请人:Lipotec S.A.；
IPC主号:

专利说明:

POLYMERICALLY COATED NANOCAPPSULES, PROCESS FOR THE PREPARATION OF POLYMERICALLY COATED NANOCAPPSULES, COSMETIC, PHARMACEUTICAL AND / OR FOOD COMPOSITION AND USE OF THE COSMETIC, PHARMACEUTICAL AND / OR FOOD COMPOSITION
FIELD OF THE INVENTION
This invention relates to a new delivery system for pharmaceutical, cosmetic and / or food active ingredients based on polymeric nanocapsules that contain water-in-oil (w / o) microemulsions and that comprise at least one hydrophilically active ingredient dissolved in the aqueous phase. .
BACKGROUND OF THE INVENTION
Solid lipid nanoparticles (SLN) are an alternative to other particulate systems for the delivery of active ingredients, such as emulsions, liposomes, micelles, microparticles and / or polymeric nanoparticles. SLNs are generated by replacing the liquid lipid in the emulsions with a solid lipid, which means that SLNs are solid at room temperature as well as at body temperature.
The use of SLN as delivery systems allows the use of physiologically acceptable lipids, the possibility of avoiding the use of organic solvents in their preparation, and a wide range of routes of administration, which includes through the skin, orally or intravenously. In addition to showing satisfactory bioavailability, its main advantages are:
1. Protection of the active ingredient against chemical degradation. The SLN lipid matrix can protect labile active ingredients against hydrolysis and / or oxidation, such as tocopherol, retinol and coenzyme Q10 [Gohla, S. et al. J. Microencapsul. 18: 149 to 158 (2001); Schaf er-Korting, M. et al. Adv. Drug Del. Rev. 59: 427 to 443 (2007)].
2/67
2. Based on the composition of the lipid particles, they offer control of the release speed of the active ingredient and, therefore, the possibility of achieving prolonged release profiles [Mehnert, W. et al. Eur. J. Pharm. Biopharm. 45: 149 to 155 (1998)].
3. Control of skin dehydration due to an occlusive effect [Muller, R.H. et al. J. Cosm. Know. 52: 313 to 323 (2001)].
4. According to their components, they can act as filters for ultraviolet radiation [Muller, R.H. et al. Int. J. Cosm. Know. 23: 233 to 243 (2001)].
A new generation of solid lipid nanoparticles is nanostructured lipid carriers (NLC). These systems have the same advantages as SLNs, and also minimize or avoid some possible problems associated with SLN, such as low loading capacity and expulsion of active ingredient during storage. In contrast to the at least partially crystalline state of the lipid phase in SLN, NLC shows a less organized solid lipid matrix. In the case of NLC, there are solid and liquid compounds in the matrix, thus, the greater disorganization leads to the existence of a greater number of holes as the subsequent increase in the ability to encapsulate active ingredients. For the preparation of NLC, sterically very different lipid molecules are mixed together, mixtures of solid lipids to lipids or liquid oils [Müller, R. H. et al. Adv. Drug Deliv. Rev. 54 (Suppl. 1): S131 to S155 (2002)].
The SLN and NLC are 50 to 1,000 nm in size and are kept stabilized in an aqueous suspension by surfactants or hydrophilic polymers. NLC and SLN are very suitable vehicles to release active ingredients through the skin. A more satisfactory penetration of active ingredients is achieved when they are
3/67 incorporated into SLN or NLC that when applied to the skin in the form of a solution or an emulsion.
SLNs have a solid lipid core that can dissolve lipophilic drugs, which is the most common case for use. However, the possibility of incorporating peptides into lipid particles could constitute a protection of the active ingredient against proteolytic degradation in the gastrointestinal tract. However, there are few references to the use of lipids as matrix materials for peptide and protein formulations, due to the hydrophobic nature of the lipid matrix, which makes it more suitable for incorporating lipophilic active ingredients than hydrophilic proteins. The use of emulsions to incorporate hydrophilically active ingredients such as insulin in SLN is described [Gallarate, M. et al. J. Microencapsul. 26: 394 to 402 (2009)]. In the publication by Gallarate et al., The SLN preparation method involves the use of organic solvents, a factor that is problematic due to the possible retention of its residues. Gasco et al. incorporates thymopentin pentapeptide in solid lipid nanoparticles by two different methods: the formation of a pair of lipophilic ions with hexadecylphosphate, or the formation of a multiple w / o / w emulsion that dissolves the peptide in the internal aqueous phase [Gasco, MR et al . J. Pharm. 132: 259 to 261 (1996)]; the latter method is also used by the same authors to incorporate an LHRH-derived polypeptide into SLN [Gasco, .R. et al. J. Pharm. 105: Rl to R3 (1994)]. Zhou et al. describes an increase in the efficiency of encapsulation and the load capacity in the incorporation in SLN of different proteins using PLGA (copolymer of lactic and glycolic acid) as an emulsifier [Zhou, W. et al. Colloids and Surfaces, B: Biointerfaces, 67: 199 to 204 (2008)].
Encapsulation of hydrophilic compounds in SLN or
4/67
NLC presents another problem, as would the diffusion of the active ingredient in the system towards a medium where it would be more soluble, that is, towards the aqueous system in which the lipid nanoparticles are in suspension.
Although SLNs and NLCs allow the chemical stability of the incorporated active ingredients to be improved, this stabilization is not complete. Surprisingly, the authors of the present invention have found greater stabilization against degradation of cosmetic and / or pharmaceutical active ingredients incorporated into SLN or NLC when the SLN or NLC are polymerically coated [Spanish patent application ES P2010-30431].
The SLN and NLC preparation procedures, as well as the delivery system described by the authors in the Spanish patent application ES P2010-30431, involve the exposure of the active ingredient to be encapsulated at the temperatures of the melting points of the lipids in the matrix, which can be very high: above 50 ° C, and in most cases, it is usual to heat the mixtures to about 80 to 90 ° C. In the case of thermolabile active ingredients, such as many biological compounds and others of synthetic origin such as synthetic peptides, this prevents the use of delivery systems based on solid lipids. The hydrophilic compounds can be incorporated into the lipid delivery system in the form of a stable microemulsion, which, as well as the stabilization of the active ingredient, promotes its bioavailability.
A microemulsion is defined as a water, oil and amphiphilic system that is an optically isotropic and thermodynamically stable solution. Microemulsions are formed spontaneously. However, ordinary emulsions require energy to form and are thermodynamically unstable [Eastoe, J. Microemulsions, in Colloid Science: principles, methods and applications, Chapter 5. Ed. T.
5/67
Cosgrove, John Wiley & Sons, Ltd (2005)].
The present invention proposes a delivery system based on polymeric nanocapsules containing microemulsions of hydrophilically active ingredients, which solves the difficulties presented by the systems described in the prior art. The substitution of solid lipids for liquid lipids within the nanocapsules prevents the exposure of the thermolabile active ingredients to the high melting temperatures of many of the lipids used in the preparation of SLN and NLC.
The delivery system of the present invention allows the nanoencapsulation of hydrophilically active thermolabile ingredients that prevent their degradation during the preparation procedure. In addition, the delivery system of the present invention allows for remarkable stabilization of the incorporated active ingredients, prevents the diffusion of hydrophilically active ingredients in the aqueous suspensions of the nanocapsules, and has a remarkable capacity for epidermal penetration.
DESCRIPTION OF THE INVENTION
The present invention provides a solution to the problems mentioned above. In a first aspect, this invention relates to a new delivery system for polymerically coated nanocapsules that contain water microemulsions in liquid oils or lipids (w / o) and that comprise at least one hydrophilically active ingredient dissolved in the internal aqueous phase.
The nanocapsules of the present invention comprise a matrix of liquid lipids or oils and a polymeric coating. A water-in-oil (w / o) emulsion of at least one hydrophilically active ingredient is incorporated into the lipid matrix. The coating of the nanocapsules forms its outer part and provides a complete and continuous coating of the
6/67 internal matrix. The terms oil and liquid lipid are used interchangeably in this invention.
The nanocapsules of the present invention contain hydrophilically active ingredients incorporated in their interior. The hydrophilically active ingredients incorporated into the nanocapsules of the present invention can be, without restriction, active ingredients and / or cosmetic, pharmaceutical and / or food adjuvants, among others.
polymeric coating of the nanocapsules of the present invention constitutes the outer barrier of the nanocapsules; allows the encapsulation of its components and also provides protection for the active ingredients. This increases its stability against chemical degradation through interaction with other possible components of the composition, through hydrolysis and / or oxidation due to the presence of oxygen and / or light. Furthermore, in the case of hydrophilically active ingredients such as peptides, this prevents the loss of the active ingredient by diffusion towards the external aqueous phase, as is often the case with aqueous SLN or NLC dispersions. Greater percutaneous penetration of the active ingredients incorporated into the nanocapsules of the invention in relation to microemulsions, liposomes, SLN and NLC is also achieved.
The procedures for preparing the nanocapsules of the present invention comprise two stages: a) preparation of the water-in-oil (w / o) emulsion of an aqueous solution of the hydrophilically active ingredient in oils or liquid lipids, and b) encapsulation of the microemulsion by means of a polymeric coating.
For the preparation of microcapsules of hydrophilically active ingredients, the mixture of liquid lipids or oils, the active ingredients, surfactants, co-active agents and / or other excipients is microemulsified with
7/67 water through stirring. Subsequently, the microemulsion is polymerically coated.
Homogenization methods such as homogenization at high pressure allow smaller particles to be obtained and use a smaller amount of surfactants.
In a particular embodiment, the droplet size of the internal microemulsion is in the range between 0.1 and 80 nm, preferably between 1 and 50 nm, and more preferably between 10 and 20 nm.
In another particular modality, in the process of preparing the nanocapsules of the present invention, the polymeric coating can be produced following the usual procedures in the prior art: physical-chemical processes (simple coacervation, complex coacervation, simple or complex coacervation with pH change during cross-linking, evaporation solvent) and chemical procedures (interfacial polycondensation). Preferably, the process used for preparing the nanocapsules of the present invention is coacervation.
When encapsulation is carried out by coacervation, the microemulsion containing the hydrophilically active ingredient dissolved in its aqueous phase is dispersed in an external aqueous solution or dispersion that contains at least one polymer of the coating and may optionally contain other active ingredients, emulsifiers, polymers and / or other excipients. The process can be carried out in only one stage if a solution of the coacervation agent (simple coacervation) or another polymer (complex coacervation) is poured under stirring in the previous w / o / w mixture.
In another particular embodiment, in the formation of the polymeric coating of the nanocapsules of the present invention, a crosslinking agent is used. The crosslinking agent is selected, for example and not restricted to, the
8/67 from the group formed by aldehydes, glutaraldehyde, formaldehyde, transglutaminases, methylenebisacrylamide derivatives, NN-methylenebisacrylamide, NN- (1,2dihydroxyethylene) bisacrylamide, ethylene glycol dimethacrylate derivatives, ethylene glycol diacrylate, ethylene glycol diacrylate, glycol diarylate tetraethylene glycol diacrylate, diethylene glycol methacrylate, diethylene glycol dimethacrylate, triethylene glycol dimethacrylate, sodium tripolyphosphate, N-hydroxysuccinamide esters and / or imidoesters.
In another particular modality, complex coacervation can be performed by increasing the pH since the coacervate has been formed and before the crosslinking is carried out. That is, the pH at which the capsule is cross-linked is higher than the coacervation pH, which allows smaller capsules to be obtained [Spanish patent application ES P2010-30432].
The nanocapsules of the present invention can be collected by the usual techniques, such as filtration, centrifugation, spray drying and / or lyophilization.
In another particular embodiment, the size of the nanocapsules of the present invention ranges between 10 and 5,000 nm, preferably between 20 and 2,000 nm, and more preferably between 50 and 1,000 nm.
percentage of incorporation of the active ingredient into the nanocapsules of the present invention is quantitative.
In another particular embodiment, the liquid lipid of the nanocapsules of the present invention has a melting point below 4 ° C, and can be liquid or semi-liquid. The liquid lipid is selected, without restriction, from the group formed by vegetable oils, such as soybean oil, sunflower oil, corn oil, olive oil, palm oil, cottonseed oil, rapeseed oil , peanut oil, coconut oil, castor oil, flax oil, borage oil, evening primrose oil; marine oils such as fish oils
9/67 and seaweed oils; petroleum-derived oils, such as mineral oil, liquid paraffin and petroleum jelly; short-chain fatty alcohols; medium chain aliphatic branched fatty alcohols; esters of fatty acids with short chain alcohols, such as isopropyl myristate, isopropyl palmitate and isopropyl stearate and isobutyl adipate; medium chain triglycerides (MCT) such as capric and caprylic triglycerides (INCI: capric / caprylic triglycerides) and other oils in the Miglyol® series; C12-C16 octanoates; fatty alcohol ethers, such as dioctyl ether, and / or mixtures thereof. Certain lipophilic active ingredients can also act as liquid lipid matrices at room temperature, for example and not restricted to, beta-carotene, vitamin E and retinol, and / or mixtures thereof.
In another particular modality, the surfactant is selected from the group formed by non-ionic surfactants, amphoteric surfactants, anionic surfactants, cationic surfactants and / or mixtures thereof. The nonionic surfactant and / or the amphoteric surfactant is selected, without restriction, from the group formed by lecithins, alkyl glycosides with an alkyl group that has 6 to 24 carbon atoms, alkylmaltosides with an alkyl group that has 6 to 24 carbon atoms, ethoxylated alkylphenols with an alkyl group having 6 to 24 carbon atoms and 5 to 30 ethylene oxide units, alkylphenol polyoxyethylene ethers with an alkyl group having 6 to 24 carbon atoms, fatty alcohols saturated and unsaturated with an alkyl group having 8 to 24 carbon atoms, poloxamers, polysorbates, fatty acid esters with sugars, sorbitan esters, polyethylene glycol fatty acid esters, castor oil, fatty alcohol ethers and polyoxyethylene , fatty acid alkanolamides, amine oxides, alkyl betaines with an alkyl group having 6 to 24 carbon atoms
10/67 carbon, acyl starch betaines, alkylsulfobetaines with an alkyl group having 6 to 24 carbon atoms, derivatives of glycine, digitonin, inulin lauryl carbamate and / or mixtures thereof. More preferably, the nonionic surfactant and / or amphoteric surfactant is selected from the group consisting of octyl glycoside, decyl glycoside, lauryl glycoside, octy fructose, dodecyl maltoside, decyl maltoside, nonoxynol-9, polyethylene glycol p- (l, l, 3,3tetramethylbutyl) phenyl ether, palmityl alcohol, oleyl alcohol, poloxamer 188, poloxamer 407, polysorbate 20, polysorbate 60, polysorbate 80, methyl glucose dioleate, sorbitan monostearate or Span 60, sorbitan monolaurate or Span 20, sorbitan monopalmitate or Span 20, sorbitan olivate, polyethylene glycol 40 stearate, polyethylene glycol 50 stearate, polyethylene glycol 100 stearate, polyoxyethylene stearyl ether, polyoxyethylene lauryl ether, cocamide monoethanolamine, cocamide diethanolamine, cocamide laethanolamine, ethanolamine; , cocamidopropylamine oxide, decyl betaine, dodecyl betaine, tetradecyl betaine, cocoyl betaine, cocamidopropyl betaine, cocamidopropyl hydroxysultaine, N-2-cocoyl amidoethyl hydroxyethylglycinate and N-2-cocoyl amidoethyl hydroxyethyl carboxy glycinate and / or mixtures thereof. The anionic surfactant is selected, without restriction, from the group formed by sulfonates such as alkylbenzene sulfonates, alkyl naphthalenes sulfonates, ethoxylated fatty alcohol sulfonates, aliphatic sulfonates, hydroxy alkane sulfonates, alkyl glyceryl sulfonate ethers, perfluorooctane sulfonate; alkyl sulfosuccinates, alkyl sulfoacetates; alkyl sulfates such as sodium sulfate and lauryl ammonium, ethoxylated alkyl sulfates; fatty ester sulfates; ethoxylated fatty alcohol sulfates; alkyl ether sulfates; acil
11/67 isocyanates; pentafluorooctanoates; carboxylates; ethoxylated alkylphenols; ammonium ethanol salts; diethanolammonium, methylammonium, dimethylammonium, trimethylammonium; alkyl taurates, acyl or fatty acids; alkyl or acyl sarcosinates; phosphates such as phosphate esters, alkyl phosphates, polyoxyethylene lauryl phosphate ether; glutamates; stearates; bile acids and their salts, such as glycolic acid and sodium glycolate, taurocholic acid and sodium taurocholate, taurodeoxycholate and / or mixtures thereof. The cationic surfactant is selected, without restriction, from the group formed by quaternary ammonium salts, such as cetyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, benzyl dimethyl hexadecyl ammonium chloride, distearyl dimethyl ammonium chloride, dilauryl dimethyl chloride ammonium, dimiristyl dimethyl ammonium chloride, cetylpyridinium chloride, benzalkonic chloride, benzethonium chloride, methyl benzethonium chloride and / or mixtures thereof. In another particular modality, the co-surfactant is selected, without restriction, from the group formed by low molecular weight alcohols and glycols, such as propanol, isopropanol, butanol and hexanol; long-chain fatty acids, such as octanoic acid and butyric acid; phosphoric acid monoesters; benzilic alcohol; bile acid salts such as sodium cholate, sodium glycolate, sodium taurocholate, sodium taurodeoxycholate and / or mixtures thereof.
In another particular modality, the antiflocculant is selected, without restriction, from the group formed by sodium citrate, sodium pyrophosphate, sodium sorbate, amphoteric surfactants, cationic surfactants and / or mixtures thereof.
In another particular modality, the viscosifier is selected, without restriction, from the group formed by cellulose ethers and esters, such as methyl cellulose,
12/67 hydroxyethyl cellulose, hydroxypropyl cellulose and sodium carboxymethyl cellulose; polyvinyl derivatives, such as polyvinyl alcohol, polyvinylpyrrolidone and polyvinyl acetate; alginates; polyacrylates, xanthans; pectins and / or mixtures thereof.
In another particular embodiment, the polymer of the polymeric coating of the nanocapsules of the present invention is selected, without restriction, from the group formed by proteins, polysaccharides, polyesters, polyacrylates, polyacrylates, copolymers and / or mixtures thereof. Preferably, the nanocapsule coating polymer is selected from the group consisting of gelatin, albumin, soy protein, pea protein, broad bean protein, potato protein, wheat protein, whey protein, βlactoglobulin, caseinates, starch wheat, corn starch, zein, alginates, carrageenans, pectins, arabinogalactans, gum arabic, xanthan gum, mesquite gum, tragacanth gum, galactomannans, guar gum, mesquite seed gum, guitosan, agar, poly (L-lysine) ), sodium dextran sulfate, carboxymethyl galactomannan, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose (HPMC), cellulose nitrate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose hydroxypropyl phthalate, succinate acetate hydroxypropyl methyl cellulose, polyvinyl acetate phthalate, poly (ecaprolactone), poly (p-dioxanone), poly (5-valerolactone), poly (p-hydroxybutyrate), poly (β-hydroxybutyrate) and β- copolymers hydroxyvalerate, poly (p-hydroxypropionate), methylacrylic acid copolymers (Eudragit® L and S), dimethylaminoethyl methacrylate copolymers (Eudragit® E), ethyl methacrylate trimethylammonium copolymers (Eudragit® polymeric RL and RS), and glycolic, polymers and copolymers of lactic and glycolic acid and
13/67 polyethylene glycol and mixtures thereof.
Depending on the properties of the polymer used for the polymeric coating of the nanocapsules of the present invention, it is possible to increase their specificity. A polymer that provides the polymeric coating with a positive charge allows the bond between the nanocapsules of the present invention and the hair or textile materials to be stronger. Optionally, the nanocapsule coating polymer of the present invention can be a cationic polymer. The cationic polymer can be a natural or synthetic polymer, for example and not restricted to, cationic cellulose derivatives, such as quaternized hydroxyethyl cellulose, which can be purchased under the name Polymer JR 400 ™ by Amerchol; cationic starches; copolymers of acrylamide and diary ammonium salt; quaternized vinylpyrrolidone / vinylimidazole polymers such as Luviquat ™ (BASF); condensation products of polyglycols and amines; polycarbonate polymers and copolymers; polymers called Merquat of polycarbonate-6, polycarbonate-7, polycarbonate-16, polycarbonate-10; polycarbonate-4 copolymers; dicocoylethylhydroxyethylammonium, graft copolymers with a cellulose skeleton and quaternary ammonium groups; quaternized collagen polypeptides such as hydroxypropyl laurdimony hydrolyzed collagen (Lamequat ™ by Griinau); quaternized wheat polypeptides; polyethylenimine; cationic silicone polymers such as amidomethicone or quaternium-22 silicone; adipic acid and copolymers of dimethylamino hydroxypropyl diethylenetriamine (Cartaretin ™ by Sandoz); copolymers of acrylic acid with dimethyldiallylammonium chloride (Merquat ™ 550 by Chemviron); derivatives of cationic chitin such as chitosan and its derivatives; condensation products of cationic alkylene dihalogen such as dibromobutane with bisdialkylamines; bis
14/67 dimethylamino-1,3-propane; derivatives of cationic guar gum such as guar hydroxypropyltrimony, Jaguar ™ CBS, Jaguar ™ C-17, Jaguar ™ C-16 by Celanese; polymers of quaternary ammonium salt such as Mirapol ™ A-15, Mirapol ™ AD-1, Mirapol ™ AZ-1 by Miranol; quaternized polysaccharide polymers of natural derivatives such as azarose; cationic proteins selected from gelatin, gum arabic; cationic polymers from the group formed by polyamides, polycyanoacrylates, polylactics, polyglycols, polyaniline, polypyrrole, polyvinylpyrrolidone, polymers and copolymers of amino silicone, polystyrene, polyvinyl alcohol, polystyrene and copolymers of vinyl oxide and maleic acid, ether and ether oxides. and methyl methacrylate copolymers; dimethylamino methacrylate, polyacrylates and cationic polymethacrylates such as Eudragit ™ RL 30 D by Rohm; polyamine derivatives optionally substituted by polyethylene glycol derivatives; polyamino acids under pH conditions where they are cationic; polyethyleneimine; derivatives of quaternized polyvinylpyrrolidone (PVP) and hydrophilic urethane polymers, as well as any mixture of the cationic groups mentioned above.
Optionally, the nanocapsule coating polymer of the present invention can comprise a plasticizer additive. The plasticizer additive is selected, without restriction, from the group consisting of alkyl esters of citric acid such as triethyl citrate, tributyl citrate, acetyl tributyl citrate and acetyl triethyl citrate, phthalates such as butyl phthalate and diethyl phthalate, glycerin, sorbitol, maltitol, propylene glycol, polyethylene glycol, glucose, sucrose, lanolin, palmitic acid, oleic acid, stearic acid, metal salts of fatty acid such as stearic acid or palmitic acid, sodium stearate, potassium stearate, propylene glycol monostearate, monoglycerides
15/67 acetylates such as monoacetyl glycerin and glyceryl triacetate or triacetin, glyceryl lecithin, glyceryl monostearate, alkyl sebacates eat dibutyl sebacate or diethyl sebacate, alkyl fumarates, alkyl succinates, medium chain triglycerides (MCT), castor oil, vegetable oils, hydrogenated oils, vegetable oils, castor oils waxes and / or mixtures thereof.
Optionally, other technical additives of the polymer can be added that enhance or facilitate the encapsulation process such as, for example, fluidizers, such as talc, colloidal silicon dioxide, glycerin, polyethylene glycol, glycerin monostearate and / or metal stearate salts.
In the context of the present invention, the term hydrophilic refers to substances that are soluble in water, with a solubility greater than 1 g per 100 ml of water at 20 ° C. In this invention, the terms hydrophilic and water-soluble are used interchangeably.
The nature of the active ingredient and / or cosmetic, pharmaceutical and / or hydrophilic food adjuvant can be synthetic or natural, or it comes from a biotechnological procedure or a combination of a synthetic procedure and a biotechnological procedure. Preferably, the hydrophilically active ingredient of the nanocapsules of the present invention is thermolabile. In the context of the present invention, it is understood that a thermolabile active ingredient is one that has a degradation equal to or greater than 0.5% after being subjected to a temperature of 80 ° C for two hours.
In a particular modality, the hydrophilic cosmetic, pharmaceutical and / or food active ingredient is selected, without restriction, from the group formed by amino acids, peptides, proteins, hydrolyzed proteins, enzymes, hormones, vitamins, minerals, sugars,
16/67 nucleotides, nucleic acids, molecules and extracts of biological and biotechnological origin, vaccines, synthetic or partially synthetic hydrophilic molecules and / or mixtures thereof.
In a particular modality, amino acids, their salts and / or derivatives, as well as the commercial mixtures that contain them, are selected, for example and not restricted to, from the group formed by serine, proline, alanine, glutamate, arginine, glycine, methionine, citrulline, methylglycine sodium diacetate (TRILON® M marketed by BASE), derivatives of cysteine-containing amino acids, in particular, N-acetyl cysteine, ergotioneine or S-carboxymethylcysteine, and / or mixtures thereof. In a particular embodiment, the peptides, or the commercial mixtures that contain them, are selected, for example and not restricted to, from the group formed by peptides for cosmetic use, such as GHK [INCI: Tripeptideo-1], acetyl-glutamil -methionyl-alanyl-isoleucine, acetyl-arginyl-phenylglycyl-phenylglycine, Bodyfensine ™ [INCI: Acetyl Dipeptide-3 Aminohexanoate], Relistase ™ [INCI: Acetyl-arginyl-diphenylglycyl-phenylglycyl-glycine-phenylglycyl-phenylglycyl-phenylglycyl valylphenylglycine, diaminopropionyl-alanyl-asparaginyl-histidine, acetyl-arginyl-asparaginyl-histidyl-citrulline-amide, Aldenine® [INCI: Hydrolyzed wheat protein, Hydrolysed soy protein, Tripeptide-1], Decorinpt® [INCI: Tripeptide Citrulline], Serilesine® [INCI: hexapeptide10], Peptide AC29 [INCI: Acetyl Tripeptide-30 Citrulline], Vilastene ™ [INCI: Lysine HCI, Lecithin, Tripeptide-10 Citrulline], dGlyage ™ [INCI: Lysine HCI, Lecithin,
Tripeptideo-9 Citrulline], Eyeseryl® [INCI: Acetyl
Tetrapeptide-5], Preventhelia® [INCI: Diaminopropionoil Tripeptideo-33], Argireline® [INCI: Acetyl Hexapeptide-8], SNAP-7 [INCI: Acetyl Heptapeptideo-4], SNAP-8 [INCI: Acetyl
17/67
Octapeptide-3], Leuphasyl® [INCI: Pentapeptide-18], Trylagen® [INCI: Pseudoalteromone Yeast Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline, Tripeptide-1], Inyline ™ [INCI : Acetyl Hexapeptideo-30], Melatime ™ [INCI: Acetyl Tripeptideo40], Thermostressine ™ [INCI: Acetyl Tetrapeptide-22] or Liporeductyl® [INCI: Caffeine, Butcherbroom Root Extract (Ruscus Aculeatus), TEA-Hydroiod, Carnitine, Era Extract (Hedera Helix), Escina, Tripeptide-1] sold by Lipotec, Matrixyl® [INCI: Palmitoil Pentapeptideo-4], Matrixyl® 3000 [INCI: Palmitoil Tetrapeptideo-7, Palmitoil Oligopeptideo], Dermaxil [INCI: Palmitoil Oligopeptideo ], Calmosensine ™ [INCI: Acetyl Dipeptide-1], Biopeptide CL ™ [INCI: Glyceryl Polymethacrylate, Propylene Glycol, Palmitoyl Oligopeptide] or Biopeptide EL ™ [INCI: Palmitoil Oligopeptide] marketed by Sederma, pseudodipeptides: IP 2000 , Trifluoroacetyl Tripeptide-2] commercial ized by IEB and Atrium, Pepha®-Timp [INCI: Human Oligopeptideo-20], ECM-Protect® [INCI: water (Aqua), Dextran, Tripeptide-2] or Melanostatine®-5 [INCI: Dextran, Nonapeptideo-1 ] marketed by Atrium Innovations, TimpPeptideo [roposed INCI: Acetyl Hexapeptide], Bronzing SF [roposed INCI: Butyryl Pentapeptide], BONT-L-Peptideo [INCI: Palmitoil Hexapeptideo-19] or ECM Modulin [roposed INCI: Palmitoiltripeptideo] marketed by Infinitec Assets, IP2000 [INCI: Dextran, Trifluoroacetyl tripeptide2] sold by Institut Europeen de Biologie Cellulaire, Syn®-Coll [INCI: Palmitoil Tripeptideo-5] sold by Pentapharm, Neutrazen ™ [INCI: Water, Butylene Glycol, Dextran, Palmitoyl Tripeptide 8], ChroNOIine ™ [INCI: Caprooil Tetrapeptideo-3] or Thymulen-4 [INCI: Acetyl Tetrapeptide-2] sold by Atrium Innovations / Unipex Group, Meliprene® [INCI: Dextran, Acetyl
18/67
Heptapeptide-1] or Melitane® [INCI: Acetyl Hexapeptide-1] marketed by Institut Europeen de Biologie Cellulaire / Unipex Group, Skinasensyl ™ [INCI: Acetyl Tetrapeptide-15] marketed by Laboratoires Serobiologiques / Cognis, Vialox® [INCI: Pentapeptideo- 3], Syn®-Ake® [INCI: Dipeptide Diaminobutyryl Benzylamide Diacetate], Syn®-Coll [INCI: Palmitoil Tripeptide-5], Syniorage ™ [INCI: Acetyl Tetrapeptide-11], Dermican ™ [INCI: Acetyl Tetrapeptide-9 ] marketed by Laboratoires Serobiologiques / Cognis, Kollaren® [INCI: Tripeptideo-1, Dextran] marketed by Institut Europeen de Biologie Cellulaire, Collaxyl® IS [INCI: Hexapeptideo-9], Laminixyl IS ™ [INCI: Heptapeptideo], Quintescine ™ IS [INCI: Dipeptideo4], UCPeptide ™ V [INCI: Pentapeptideo] or AT Peptide ™ IS [INCI: Tripeptideo-3] sold by Vincience / ISP, glutathione, carnosine and / or mixtures thereof; and pharmaceutical peptides, such as glucagon, leuprolide, goserelin, triptorelin, buserelin, nafarelin, deslorelin, histrelin, avoreline, abarelix, cetrorelix, ganirelix, degarelix, desmopressin, somatostatin, and somatostatin analogs, among others, and vaideotide, and vaideide.
In another particular modality, proteins, hydrolyzed protein, enzymes and hormones, as well as the commercial mixtures that contain them, are selected, for example and not restricted to, from the group formed by Elhibin® [INCI: Soy Protein (Beans Glycine], Preregen® [INCI: Soy Protein (soybean) Glycine, Oxide Reductases] or Regu®-Age [INCI: Hydrolyzed Rice Bran Protein, Soy Protein (Soybean) Glycine, Oxide Reductases] sold by Pentapharm / DSM, cadherins, integrins, selectins, hyaluronic acid receptors, immunoglobulins, growth factor of
19/67 fibroblast, connective tissue growth factor, platelet-derived growth factor, vascular endothelial growth factor, epidermal growth factor, insulin-like growth factor, keratinocyte growth factor, colony stimulus growth factor , beta transformation growth factor, alpha tumor necrosis factor, interferons, interleukins, matrix metalloproteinases, receptor protein tyrosine phosphatases, hydrolyzed vegetable proteins such as hydrolyzed wheat protein, hydrolyzed soy protein or hydrolyzed whey protein, Lipeptideo [INCI: Hydrolyzed vegetable protein] by Lipotec, Collalift® [INCI: Hydrolyzed Malt Extract] sold by Coletica / Engelhard, Colhibin [INCI: Hydrolyzed Rice Protein] sold by Pentapharm, Cytokínol® LS [INCI: Hydrolyzed Casein, Protein Hydrolyzed Yeast, Lysine HCL] marketed by Laboratoires Serobiologiques / Cognis, Liftline® [INCI: Hydrolyzed Wheat Protein] or Ridulisse C® [Hydrolyzed Soy Protein] marketed by Silab, catalase, superoxide dismutase, lactoperoxidase, glutathione peroxidase, lactoprotein, casein, lactoperoxidase, lysozyme, glucosidase, chemotypic enzyme SC, kernel layer SC proteases such as trypsin, chymotrypsin, sutilain, papain or bromelain, DNA repair enzymes such as photoliase or T4 endonuclease V, lipase, luteinizing hormone (LH), follicle stimulating hormone (FSH), growth hormone, insulin and / or mixtures thereof.
In another particular modality, vitamins are selected, for example and not restricted to, from the group formed by water-soluble vitamins, such as vitamin C, vitamin BI, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9 , vitamin B12, carnitine and / or mixtures thereof.
20/67
In another particular modality, extracts of biological or biotechnological origin, which can be chemically modified, as well as the commercial mixtures that contain them, are selected, for example and not restricted to, from the group formed by plant extracts, marine extracts, cell extracts and extracts produced by microorganisms.
The plant extracts are selected from the group formed by water-soluble plant extracts, for example and not restricted to, water-soluble extracts of chamomile, ivy, lemon, ginseng, raspberry, roasted amaranth, Rehmannias radix, gardenia, carrot, orange, peach, pineapple, gentian , hibiscus flower, walnut leaf, pumpkin, peony, quinoa, bilberry, rough vines, sage, pomegranate, oregano, ginger, marjoram, blackberry, grape, tomato, green tea, black tea, aloe vera (Aloe Barbadensis), Saphora japonica, papaya, pineapple, pumpkin, sweet potato, Bupleurum Chinensis, Cecropia Obtusifolia, Gelosia Cristata, Centella Asiatica, Chenopodium Quinoa, Chrysanthellum Indicum, Citrus Aurantium Amara, Coffea Arabica, Coleus Forskohlii, Commiphora Myrrha, Crithmum Maritim, Crithmum Maritim, Crithmum Maritim , Hedera Helix (ivy), Hibiscus Sabdariffa, Ilex Paraguariensis, Laminana Digitata, Nelumbium Speciosum, Paullinia Cupana, Peumus Boldus, Phyllacantha Fibrosa, Prunella Vulgaris, Prunus Amygdalus Dulcis , Ruscus Aculeatus (extract from Butcherbroom), Sambucus Nigra, Spirulina Platensis Algae, Uncaria Tomentosa, Verbena Officinalis, Opuntia ficus indica, Salix alba, Lupinus spp., Secale cereale, Tussilago farfara, Achillea millefolis, Aradiruna, Aradiruna , Bidens pilosa, Broussonetia papyrifera, Chlorella vulgaris, Cimicifuga racemosa, Emblica officinalis, Glycyrrhiza glabra, Glycyrrhiza uralensis, Ilex purpureia, Ligusticum lucidum,
21/67
Ligusticum wallichii, Mitracarpus scaber, Morinda citrifolia, Morus alba, Morus bombycis, Naringi crenulata, Prunus domesticus, Pseudostellariae radix, Rumex crispus, Rumex occidentalis, Sapindus mukurossi, Saxifragia sarmentosa, Medutellaria sarmentic, Scutellaria ursi, Whitania somnifera, Aristoloquia clematis, Rosa moschata, Echinacea angustifolia, Symphytum officinale, Equisetum arvense, Hypericum perforatum, Mimosa tenuiflora, Persea gratíssima, Prunus africanum, Tormentilla erectea, Solanum tuberosic, pyridisis, Macrolinea, Rosmarinus , Malpighia punicitolia, Cynara scolymus, Gossypium herbaceum, Panicum miliaceum, Morus nigra, Sesamum indicum, Glycine soy, Triticum vulgare, Glycine Max (soy), malt, flax, red cloves, kakkon-to, white lupine, hazelnut, more, hazelnut, more beech tree, Trifolium pratense (red carnation), Phormium tenax (New Zealand flax), Cin namommum zeylanicum, Laminaria saccharina, Spiraea ulmaria, Nettle Root, Pygeum africanum, Avena Sativa, Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita, Rosmarinus officinalis extratus, Symex, Thym of vegetable seeds, red seaweed extracts of the genus Porphyra, Phytovityl C® [INCI: Water, Green Corn Extract (Zea Mays)] sold by Solabia, Micromerol ™ [INCI: Pyrus Malus Extract] or Heather Extract [INCI : Calluna Vulgaris Extract] sold by Coletica / Engelhard / BASF, Proteasyl® TP LS8657 [INCI: Pisum Sativum Extract] sold by Laboratoires Serobiologiques / Cognis, Radicaptol [INCI: Propylene Glycol, Water, Passiflora Incarnata Flower Extract, Extract of Ribes Nigrum (blackcurrant) Leaf, Vitis Vinifera Leaf Extract (grape)]
22/67 sold by Solabia or ViaPure ™ Boswellia [INCI: Olivanum Extract (Boswellia Serrata)] sold by Soliance, EquiStat [INCI Pyrus Malus Fruit Extract, Glycine Soybean Extract] sold by Coletica / Engelhard, Litchiderm ™ [INCI: Litchi Chinensis pericarp extract] or Arganyl ™ [INCI: Argania Spinosa Leaf Extract] commercialized by Laboratories Serobiologiques / Cognis, Dakaline [INCI: Prunus amygdalus dulcis, Anogeissus leiocarpus bark extract] commercialized by Soliance, Actimp 1.9.3® [INCI: Hydrolyzed Lupine Protein] marketed by Expanscience Laboratorios, Pronalen® Refirming HSC [INCI: Triticum vulgare, Silybum Marianum, Soybum Glicina, Equisetum Arvense, Alchemilla Vulgaris, Medicago Sativa, Raphanus Sativus] or Poliplant® Refming INCI: Coneflower, Asiatic Centella, Fucus, Fenugreek] sold by Provital, Lanablue® [INCI: Sorbitol, Seaweed Extract] sold by Atrium Innovations, Firmiderm® LS 9120 [INCI: Terminalia Catappa Leaf Extract, Black Sambucus Flower Extract, PVP, Tannic Acid] sold by Laboratoires Serobiologiques / Cognis, among others.
Cell extracts and extracts produced by microorganisms, or commercial mixtures containing them, are selected from the group consisting of cellular water-soluble extracts and water-soluble extracts produced by microorganisms, for example and not restricted to, Antarcticine® [INCI: Yeast Extract Pseudoalteromonas] and Trylagen® [INCI: Pseudoalteromone Yeast Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Citrulline, Tripeptide-1] marketed by Lipotec, yeast extract, Saccharomyces cerivisiae extract and the product of fermentation cerivisiae and the product of fermentation cerivisiae milk with Lactobacillus Bulgaricus, among others.
23/67
The amount of hydrophilically active ingredient contained in the delivery system of the present invention is in the range between 0.00001 and 50% by weight, preferably between 0.0001 and 40% by weight, and more preferably between 0.001 and 30% by weight.
In another particular embodiment, the nanocapsules of the present invention comprise other active ingredients and / or cosmetic and / or food adjuvants of any nature, hydrophobic, hydrophilic and amphiphilic, which can be found inside the nanocapsules in solution or in suspension in the lipid matrix, or in the aqueous phase of the microemulsion. In particular, the active ingredients and / or cosmetic and / or food adjuvants are selected, for example and not restricted to, from the group formed by surfactants, humectants or substances that retain moisture, moisturizers or emollients, agents that stimulate healing, supporting healing agents, agents that stimulate re-epithelialization, supporting re-epithelialization agents, agents that synthesize dermal or epidermal macromolecules, firmness and / or redensification and / or restructuring agents, cytokine growth factors, agents that act in capillary circulation and / or microcirculation, anti-glycation agents, free radical scavengers and / or anti-atmospheric pollution agents, scavengers of active carbonyl species, 5th reductase inhibiting agents, lysyl and / or prolyl reductase inhibiting agents, defensin synthesis stimulating agents, bactericidal agents and / or bacteriostatic agents and / or antimicrobial agents and / or germicidal agents and / or u fungicidal agents and / or fungistatic agents and / or germ inhibiting agents, antiviral agents, antiparasitic agents, antihistamine agents, NO synthase inhibiting agents, peeling agents or kerotolytic agents and / or exfoliating agents, agents
24/67 comedolytic agents, antipsoriase agents, anti-dandruff agents, anti-inflammatory and / or analgesic agents, anesthetic agents, anti-wrinkle and / or anti-aging agents, deodorants for masking body and / or cosmetic and / or absorbent odor, antiperspirants, substances for perfuming and / or perfumed oils and / or isolated aromatic compounds, antioxidating agents, agents that inhibit vascular permeability, hydrolytic epidermal enzymes, skin bleaching or depigmentation agents, agents that inhibit sweat-degrading enzymes, agents that have the ability to filter UV rays, agents that stimulate or regulate keratinocyte differentiation, anti-itch agents, agents that stimulate or inhibit melanin synthesis, pro-pigmentation agents, self-tanning agents, melanocyte proliferation stimulating agent, liquid propellants, vitamins, amino acids, proteins , biopolymers, gelling polymers, skin relaxers, agents that have the ability to reduce or treat bags over the eyes, agents for the treatment and / or care of sensitive skin, astringent agents, agents that regulate sebum production, anti-stretch agents, lipolytic agents or agents that stimulate lipolysis, venotonic agents, anti-cellulite agents , soothing agents, agents that act on cell metabolism, agents to improve the dermal-epidermal junction, agents that induce hair growth or hair loss retardants, agents that inhibit or delay hair growth, agents that stimulate protein synthesis by thermal shock, muscle relaxants, muscle contraction inhibiting agents, agents that inhibit acetylcholine receptor clustering, cholinergic agents, elastase inhibiting agents, matrix metalloproteinase inhibiting agents, chelating agents, plant extracts, essential oils, marine extracts, salts
25/67 minerals, cell extracts, emulsifying agents, agents that stimulate the synthesis of lipids and components of the horny layer (ceramides, fatty acids, etc.), agents obtained from a process of biofermentation and / or mixtures thereof. The nature of these active ingredients and / or cosmetic and / or food adjuvants can be synthetic or natural, such as plant extracts, or from a biotechnological process or a combination of a synthetic process and a biotechnological process. Additional examples can be found in the CTFA International Cosmetic Ingredient Dictionary & Handbook, 12th Edition (2008). In the context of the present invention, it is understood that a biotechnological process is any process that produces the active ingredient, or part of it, in an organism, or in a part of it.
In a particular embodiment, the humectant or substance that retains moisture, moisturizer or emollient is selected, for example and not restricted to, from the group formed by polyols and polyethers such as glycerin, ethylhexylglycerine, caprylyl glycol, pentylene glycol, butylene glycol, propylene glycol and its derivatives, triethylene glycol, polyethylene glycol, Gliceret-26, Sorbet30; panthenol; pyroglutamic acid and its salts and derivatives; amino acids, such as serine, proline, alanine, glutamate or arginine; ectoin and its derivatives; N- (2-hydroxyethyl) acetamide; N-lauroyl-pyrrolidone carboxylic acid; N-lauroyl-L-lysine; N-alpha-benzoyl-L-arginine; urea; creatine; α and β-hydroxy acids such as lactic acid, glycolic acid, malic acid, citric acid or salicylic acid, and their salts; polyglyceryl acrylate; sugars and polysaccharides, such as glucose, saccharide isomerate, sorbitol, pentaerythritol, inositol, xylitol, trehalose and derivatives thereof, sodium glucuronate, carrageenates
26/67 (Chondrus crispus) or chitosan; glycosaminoglycans such as hyaluronic acid and derivatives thereof; aloe vera in any of its forms; honey; soluble collagen; lecithin and phosphatidylcholine; ceramides; cholesterol and its esters; tocopherol and its esters, such as tocopheryl acetate or tocopheryl linoleate; long-chain alcohols such as cetearyl alcohol, stearyl alcohol, cetyl alcohol, oleyl alcohol, isocetyl alcohol or octadecan-2-ol; long chain alcohol esters such as lauryl lactate, myristyl lactate or C12-C15 alkyl benzoates; fatty acids such as stearic acid, isostearic acid or palmitic acid; polyunsaturated fatty acids (PUFAs); sorbitans as sorbitan distearate; glycerides such as glyceryl monoricinoleate, glyceryl monostearate, glyceryl stearate citrate or caprylic and capric acid triglyceride; sucrose esters such as sucrose palmitate or sucrose oleate; butylene glycol esters, such as Dicaprilat and Dicaprato; fatty acid esters such as isopropyl isostearate, isobutyl palmitate, isocetyl stearate, isopropyl laurate, hexyl laurate, decyl oleate, cetyl palmitate, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl ester, isopropyl ester butyl stearate, butyl myristate, isopropyl linoleate, 2-ethylhexyl palmitate, 2-ethylhexyl cocoate, decyl oleate, myristyl myristate; squalene; mink oil; lanolin and its derivatives; acetylated lanolin alcohols; silicone derivatives such as cyclomethicone, dimethicone or dimethylpolysiloxane; Antarcticine® [INCI: Pseudoalteromone Yeast Extract] or acetyl-glutamyl-methionyl-alanylisoleucine, acetyl-arginyl-phenylglycyl-phenylglycine or acetyl-arginyl-6-aminohexanoyl-alanine marketed by Lipotec, petrolatum; mineral oil; mineral waxes and
27/67 synthetic; beeswax (wax alba); paraffin; or vegetable waxes and oils such as candelilla wax (Euphorbia cerifera), carnauba wax (Copernicia cerifera), shea butter (Butirospermum parkii), cocoa butter (Theobroma cacao), castor oil (Ricinus communis), oil sunflower (Helianthus annuus), olive oil (Olea europaea), coconut oil (Cocos nucifera), palm oil (Elaeis guineensis), wheat germ oil (Triticum vulgare), sweet almond oil (Prunus amygdalus dulces), musk rose oil (Rosa moschata), soybean oil (Glycine soy), grape seed oil (Vitis vinifera), marigold oil (Calendula officinalis), jojoba oil (Simmonsis chinensis), mango oil ( Mangifera indica), avocado oil (Persea gratíssima), and / or mixtures thereof, among others.
Likewise, in another particular modality, the agent that stimulates healing, the supporting healing agent, the agent that stimulates reepithelization and / or the supporting reepithelization agent is selected, for example and not restricted to, from the group formed by extracts of Aristoloquia clematis, Centella asiatica, Rosa moschata, Echinacea angustifolia, Symphytum officinale, Equisetum arvense, Hypericum perforatum, Mimosa tenuiflora, Persea gratisima, Prunus africanum, Tormentilla erectea, Aloe vera, Poliplant® Epithelizing, Chamomilla Recutita, Rosmarinus Officinalis] sold by Provital, Cytokinol® LS 9028 [INCI: Hydrolyzed Casein, Hydrolyzed Yeast Protein, Lysine HCI] sold by Laboratories Serobiologiques / Cognis or Deliner® [INCI: Zea May Core Extract (Corn)] marketed by Coletica / Engelhard / BASF, allantoin, cadherins, integrins, selectins, hyaluronic acid receptors, immunoglobulins, fibroblast growth factor,
28/67 connective tissue, platelet-derived growth factor, vascular endothelial growth factor, epidermal growth factor, insulin-like growth factor, keratinocyte growth factor, colony stimulating factors, transforming beta growth factor, alpha tumor necrosis factor, interferons, interleukins, matrix metalloproteinases, receptor protein tyrosine phosphatases, Antarcticine® [INCI: Pseudoalteromone Yeast Extract], Decorinyl® [INCI: Tripeptide-10 Citrulline], Trylagen® [INCI: Extract Pseudoalteromone Yeast, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline, Tripeptide-1], Bodyfensine ™ [INCI: Acetyl Dipeptide-3 Aminohexanoate], marketed by Lipotec, among others.
In a particular embodiment, the agent that stimulates dermal or epidermal macromolecular synthesis is selected, for example and not restricted to, from the group formed by agents that stimulate collagen synthesis, agents that stimulate elastin synthesis, agents that stimulate decorin synthesis , agents that stimulate synthesis of laminin, agents that stimulate synthesis of chaperone, agents that stimulate synthesis of sirtuin, agents that stimulate synthesis of hyaluronic acid, agents that stimulate synthesis of aquaporin, agents that stimulate synthesis of fibronectin, agents that inhibit collagen degradation , agents that inhibit
degradation of elastin, agents that inhibit serine proteases as a leukocyte elastase or cathepsin G, agents that stimulate proliferation in fibroblast, agents what stimulate proliferation in adipocyte, agents what stimulate differentiation in adipocyte, agents what stimulate angiogenesis, agents that stimulate synthesis of
glycosaminoglycan, DNA repair agents and / or DNA protection agents, for example and not restricted to, extracts of
29/67
Centella aslatlca, Saccharomyces cerevisiae, Solanum tuberosum, Rosmarinus officinalis, Vaccinium angustifolium, Macrocystls pyrifera algae extract, Radina pavonica, soy plant extract, malt, flax, sage, red cloves, kakkon-to, white lupine extract, white lime extract, extract corn, yeast extract, beech branch extract, legume seed extract, vegetable hormone extract such as gibberellins, auxins or cytokinins among others, or zooplankton extract Saline, the product of milk fermentation with Lactobacillus Bulgaricus, asiaticosídeos and derivatives thereof, vitamin C and derivatives thereof, cinnamic acid and derivatives thereof, Matrixyl® [INCI: Palmitoil, Pentapeptideo-3], Matrixyl® 3000 [INCI: Palmitoil Tetrapeptideo-3, Palmitoil Oligopeptide] or Biopeptide CL ™ [INCI : Glyceryl Polymethacrylate, Propylene Glycol, Palmitoyl Oligopeptide] sold by Sederma, Antarcticine® [INCI: Pseudalteromonas Yeast Extract], Decorinyl® [INCI: Tripeptide-10 Citrulline], Serilesine® [INCI: Hexapeptide-10], Lipeptide [INCI: Hydrolyzed Vegetable Protein], Aldenine® [INCI: Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-1], AC29 Peptide [INCI: Tripeptide-30 Citrulline Acetyl] marketed by Lipotec, Drieline® PE [INCI: Yeast beta-glucan] marketed by Alban Muller, Phytovityl C® [INCI: Water, Green Corn Extract (Zea Mays)] marketed by Solabia, Collalift® [INCI : Hydrolyzed Malt Extract] marketed by Coletica / Engelhard, Phytocohesine® PSP [roposed INCI: BetaSitosterol Sulfate Sodium] marketed by Seporga, minerals such as calcium, among others, retinoids and derivatives thereof, isoflavonoids, carotenoids, in particular, lycopene, pseudodipeptides , retinoids and derivatives thereof such as retinol or retinyl palmitate, among others,
30/67 or heparinoids, among others.
In an particular modality, the agent who inhibits degradation from el astina is selected, for example and not restricted The, from the formed group by Elhibin® [INCI: Protein in Soy (Soybean) Glycine ], Preregen® [INCI: Protein in Soy (soybean) Glycine, Oxide Reductas and I'm Regu®-Age [ INCI: Bran Protein Hydrol Rice isada, Protein in Soy (Soybean) Glycine , Oxide Reductases] marketed by Pentapharm / DSM, Youthful [INCI:
Etoxidiglycol and caprylic triglyceride, Retinol, Ursolic Acid, Phytonadione, llomastat], Micromerol ™ [INCI: Pyrus Malus Extract], Heather Extract [INCI: Calluna Vulgaris Extract], Extracellium® [INCI: Hydrated Potato Protein] or Extracellium® ™ PEG [INCI: PEG-6 Isostearate, Hesperetin Laurate] marketed by Coletica / Engelhard / BASF, Proteasyl® TP LS8657 [INCI: Pisum Sativum Extract] marketed by Laboratoires Serobiologiques / Cognis, Relistase ™ [INCI: Acetilarginyltriptofil Difenylglyclicized] by Lipotec, Sepilift DPHP [INCI: Dipalmitoyl hydroxyproline] marketed by SEPPIC, Vitaderm® [INCI: Alcohol, Water, Glycerin, Hydrolyzed Rice Protein, Ilex Aquifolium Extract, Sodium Ursolate, Sodium Oleanolate] marketed by Rahn, Gatuline® Age Defense 2 [INCI: Juglans Regia Seed Extract (Walnut)] marketed by Gattefosse, IP 2000 [INCI: Dextran, Trifluoroacetyl Tripeptide-2] marketed by IEB and Atrium, Radicaptol [INCI : Propylene Glycol, Water, Passiflora Incarnata Flower Extract, Ribes Nigrum Leaf Extract (blackcurrant), Vitis Vinifera Leaf Extract (grape)] marketed by Solabia or ViaPure ™ Boswellia [INCI: Olivanum Extract (Boswellia Serrata )] sold by Soliance, among others.
31/67
In a particular embodiment, the matrix metalloproteinase inhibiting agent is selected, for example and not restricted to, from the group formed by ursolic acid, isoflavones such as genistein, quercetin, carotenoids, lycopene, soy extract, blackberry extract, rosemary extract, Tri folium pratense extract (red cloves), Phormium tenax extract (New Zealand flax), kakkon-to extract, sage extract, retinol and derivatives thereof, retinoic acid and derivatives thereof, sapogenins such as diosgenin, hecogenin, smilagenin, sarsapogenin, tigogenin, iamogenin and iucagenin, among others, Collalift® [INCI: Hydrolyzed Malt Extract], Juvenile [INCI: Caprylic Etoxidiglycol and Triglyceride, Retinol, Ursolic Acid, Fitonadione or Fitonadione] Malus Fruit Extract, Glycine Soybean Seed Extract] marketed by Coletica / Engelhard, Pepha®-Timp [INCI: Human Oligopeptide-20], Regu-Age [INCI: Hi Rice Bran Protein drolised, Soy Glycine Protein, Oxide Reductases] or Colhibin [INCI: Hydrolyzed Rice Protein] sold by Pentapharm, Lipeptide [INCI: Hydrolyzed vegetable protein], AC29 peptide [INCI: Acetyl Tripeptide-30 Citrulline], acetyl-arginyl- asparaginilhistidil-citrulin-amide marketed by Lipotec, Litchiderm ™ [INCI: Litchi Chinensis pericarp extract] or Arganyl ™ [INCI: Argania Spinosa Leaf Extract] marketed by Laboratories Serobiologiques / Cognis, MDI Complex® [INCI: glycosaminoglycans] or ECM-Protect® [INCI: water (Aqua), Dextran, Tripeptide-2] sold by Atrium Innovations, Dakaline [INCI: Prunus amygdalus dulcis, Anogeissus leiocarpus bark extract] sold by Soliance, Homeostatina [INCI: Enteromorpha compressa, Caesalpinia Spinosa] commercialized by Provital, TimpPeptideo [roposed INCI: Acetyl Hexapeptideo] or ECM Modulina
32/67
[Proposed INCI: Palmitoyltripeptide] sold by Infinitec Activos, IP2000 [INCI: Dextran, Trifluoroacetyl tripeptide-2] sold by Institut Europeen de Biologie Cellulaire, Actimp 1.9.3® [INCI: Hydrolyzed Lupine Protein] sold by Expanscience Laboratories, Vitaderm® [INCI: Alcohol, water (Water), Glycerin, Hydrolyzed Rice Protein, Ilex Aquifolium Extract, Sodium Ursolate, Sodium Oleanolate] marketed by Rahn, adapalene, tetracyclines and derivatives thereof such as minocycline, rolitetracycline, chlortetracycline, metacycline, oxytetracycline, doxycycline, demeclocycline and its salts, Batimastat [BB94; [4- (N-hydroxyamino) -2R-isobutyl-3S (thiophene-2-ylthiomethyl) succinyl] -L-phenylalanine-Nmethylamide], Marimastat [BB2516; [2S— [N4 (R *), 2R *, 3S]] - N4 [2,2dimethyl-1- [methylaminocarboni1] propyl] -NI, 2-dihydroxy-3- (2methylpropyl) butanediamide], among others.
In a particular modality, the firmness and / or redensification and / or restructuring agent is selected, for example and not restricted to, from the group formed by extracts of Malpighia punicitolia, Cynara scolymus, Gossypium herbaceum, Aloe Barbadensis, Panícum miliaceum, Morus nigra, Sesamum indicum, Glycine soy, Triticum vulgare, Pronalen® Refirming HSC [INCI: Triticum vulgare, Silybum Marianum, Soy Glicina, Equisetum Arvense, Alchemilla Vulgaris, Medicago Sativa, Raphanus Sativus] or Poliplant® Refirming: Centetla, Fucus, Fenugreek] sold by Provital, Lanablue® [INCI: Sorbitol, Seaweed Extract] sold by Atrium Innovations, Pepha®-Nutrix [INCI: Natural Nutrition Factor] sold by Pentapharm, or plant extracts that contain isoflavones, Biopeptide EL ™ [INCI: Palmitoil Oligopeptide], Biopeptide CL ™ [INCI: Palmitoil
Oligopeptide], Vexel® [INCI: water (Water), Propylene Glycol,
33/67
Lecithin, Caffeine, Palmitoil Carnitine], Matrixyl® [INCI: Palmitoil Pentapeptideo-3], Matrixyl® 3000 [INCI: Palmitoil Tetrapeptideo-3, Palmitoil Oligopeptideo] or Bio-Bustyl ™ [INCI: Glyceril Polymethacrylate, Soy protein yeast Rahnella, water (Aqua), Propylene Glycol, Glycerin, PEG-8, Palmitoyl Oligopeptide] sold by Sederma, Dermosaccharides® HC [INCI: Glycerin, water (Aqua), Glycosaminoglycans, Glycogen], Aglycal® [INCI: Mannitol, Cyclodextrin, Glycogen, Aratostaphylos Uva Ursi Leaf Extract], Cytokinol® LS [INCI: Hydrolyzed Casein, Hydrolyzed Yeast Protein, Lysine HCI] or Firmiderm® LS9120 [INCI: Terminalia Catappa Leaf Extract, Black Sambucus Flower Extract, PVP , Tannic Acid] marketed by Laboratoires Serobiologiques / Cognis, Liftline® [INCI: Hydrolyzed Wheat Protein], Raffermine® [INCI: Hydrolyzed Soy Flour] or Ridulisse C® [Hydrolyzed Soy Protein] marketed by Silab, Serilesine® [INCI : hexapept ideo-10], Decorinyl ™ [INCI: Tripeptide-10 Citrulline], Trylagen® [INCI: Pseudoalteromone Yeast Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline, Tripeptide-1], marketed by Lipotec , Ursolisome® [INCI: Lecithin, Ursolic Acid, Atelocolagen, Xanthan gum, Chondroitin Sodium Sulfate] or Collalift® [INCI: Hydrolyzed Malt Extract] marketed by Coletica / Engelhard, Syn®-Coll [INCI: Palmitoil Tripeptide-5] marketed by Pentapharm, Hydriame® [INCI: water (water), glycosaminoglycans, sclerotum gum] marketed by Atrium Innovations or IP2000 [INCI: Dextran, trifluoroacetyl tripeptide-2] marketed by Institut Europeen de Biologie Cellulaire, among others.
In a particular embodiment, the anti-glycation agent is selected, for example and not restricted to, from the
34/67 group formed by extracts of Vaccinium angustifolium, ergotioneine and derivatives thereof, lysine, Aldenine® [INCI: Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptideo-1], Vilastene ™ [INCI: Lysine HCI, Lecithin, Tripeptide -10 Citrulline], dGlyage ™ [INCI: Lysine HCI, Lecithin, Tripeptide-9 Citrulline] or Eyeseryl® [INCI: Acetyl Tetrapeptide-5] marketed by Lipotec, hydroxystilbenes and derivatives thereof, resveratrol or 3.3 ', 5, 5'tetrahydroxystilbene, among others.
In a particular embodiment, the free radical scavenger and / or atmospheric antipollution agent, and / or the reactive carbonyl scavenger is selected, for example and not restricted to, from the group formed by tea extract, olive leaf, Rosmarinus officinalis extract or Eichhornia crassipes extract, benzopyrenes, vitamin C and derivatives thereof, vitamin E and derivatives thereof, in particular, tocopheryl acetate, ascorbyl glycoside, phenols and polyphenols, in particular, tannins, acid tannic and ellagic acid, galocatechol, anthocyanins, chlorogenic acid, stilbenes, indoles, amino acid derivatives containing cysteine, in particular, Nacetylcysteine, ergotioneine, S-carboxymethylcysteine, chelating agents, in particular, EDTA or ethylenediamines, carotenoids, bioflavonoids, bioflavones; , catalase, superoxide dismutase, lactoperoxidase, glutathione peroxidase, glutathione, benzylidene camphor, pidolates, lignans, melatonin, oryzanol, carnosine and derivatives thereof, GHK [INCI: Tripeptide-1] and its salts and / or derivatives, Aldenine® [INCI: Hydrolyzed Wheat Protein, hydrolyzed soy protein, tripeptide-1], Preventhelia® [INCI: Diaminopropionoil Tripeptide- 33], diaminopropionyl-alanilasparaginylhistidine or Lipochroman-6 [INCI: Dimethylmethoxy Cromanol] marketed by Lipotec, among others.
35/67
In a particular embodiment, the 5a reductase inhibiting agent is selected, for example and not restricted to, from the group formed by Cinnamommum zeylanicum extract, Laminaria saccharins, Spiraea ulmaria, Nettle Root, Pygeum africanum, Avena Sativa, Serenoa repens, plant extracts Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita, Rosmarinus officinalis, Salvia officinalis, Salvia officinalis, plant extract of the genus Silybum, plant extract containing sapogenins and in particular extract from plants of the genus Dioscorea, phytosterdis, retinoids and, in particular, retinol, sulfur and derivatives thereof, zinc salts and, in particular, lactate, gluconate, pidolate, carboxylate, salicylate or zinc cystate, selenium chloride, vitamin B6, pyridoxine, capryloyl glycine, sarcosine, finasteride, dutasteride, izonsteride, turosteride and their salts, among others.
Likewise, in another particular modality, the lysyl and / or prolyl hydroxylase inhibiting agent is selected, for example and not restricted to, from the group formed by 2,4-diamiriopyrimidine 3-oxide or 2,4-diamino -6piperidinopyrimidine 3-oxide, among others.
In another particular modality, the defensin-stimulating agent is selected, for example and not restricted to, from the group formed by extracts of Aloe Vera, roasted Amaranth, Rehmannlas radix, arnica, gardenia, carrot, orange, peach , pineapple, mint, gentian, hibiscus flower, walnut leaf, calabash, peony, guinea, bilberry, rough creeper, sunflower, elderberry, seagrass, hydrolyzed corn, hydrolyzed soy, hydrolyzed rice, hydrolyzed valine and its isomers and derivatives, calcium and its salts, σ-MSH and fragments contained in the amino acid sequence of σ-MSH, vitamin A and
36/67 its derivatives and precursors, vitamin D3 and its derivatives, jasmonic acid, fumaric acid, malic acid, citric acid, ascorbic acid, lactic acid, acetic acid, adipic acid, tartaric acid, cinnamic acid, glutamic acid, succinic acid, inulin, alkyl glycosides, polyglutamic acid, glycine, L-methionine, L-alanine, L-citrulline, lactoprotein, casein, lactoperoxidase, lysozyme, polyphenol, alkyl glycosides, Lactobacillus extract, fusobacterium extracts or non-photosynthetic bacteria fruit and Bodyfensine ™ [INCI: Acetyl Dipeptide-3 Aminohexanoate] marketed by Lipotec, among others.
In another particular embodiment, the bactericidal and / or bacteriostatic agent and / or antimicrobial and / or germicidal agent and / or fungicidal agent and / or fungistatic agent and / or germ inhibiting agent is selected, for example and not restricted to, the from the group formed by macrolides, pyranosides, calcium channel blockers, for example and not restricted to, cinnarizine and diltiazem; hormones, for example and not restricted to, strila, analogues of the same or thyroxine and / or its salts, caprylyl glycol, imidazolidinyl urea, methyl 4-hydroxybenzoate [INCI: methylparaben], ethyl 4hydroxybenzoate [INCI: ethylparabene], propyl 4hydroxybenzoate [INCI: : propylparaben], butyl 4hydroxybenzoate [INCI: butyl paraben], isobutyl 4hydroxybenzoate [INCI: isobutylparaben], 1,3bis (hydroxymethyl) -5,5-dimethylimidazolidine-2,4-dione [INCI: DMDM Hydantoin], benzyl 4-hydroxy [INCI: benzylparaben], benzyl alcohol, dehydroacetic acid, benzoic acid, sorbic acid, salicylic acid, formic acid, propionic acid, 2-bromo-2-nitropropane-1,3-diol,
3-p-chlorophenoxy-1,2-propanediol [INCI: chlorphenenesin], dichlorobenzyl alcohol, iodopropynyl butylcarbamate, benzalkonic chloride, odor-absorbing fungicides such as ricinoleate
37/67 zinc, cyclodextrins, benzetonic chloride, chlorhexidine, ethanol, propanol, 1,3-butanediol, 1,2-propylene glycol, undecylenic acid, dehydroacetic acid, N-methylmorpholine acetonitrile (ΜΜΆ), isopropanol, methanol, 1,2hexanediol , 1,2-octanodiol, pentylene glycol, glycerin laurate, glycerin caprylate, glycerin caprate, benzoyl peroxide, chlorhexidine gluconate, triclosan and derivatives thereof, phenoxyethanol, terpinen-4-ol, oterpineol, resorcinol, estiemicina, erythromycin, neomycin, clindamycin and its esters, tetracyclines, metronidazole, azelaic acid, tolnaftate, nystatin, clotrimazole, ketoconazole, zinc derivatives such as zinc pyrithionate or trithionate, zinc oxide and zinc undecylenate, pyrochloride olamine, isotonic acid, olefin, isotonic acid, zinc hemiformal benzyl, boric acid, sodium borate, 6,6-dibromo-4,4-dichloro-2,2'methylenediphenol [INCI: bromochlorophene], 5-bromo-5-nitro-1, 3dioxane, sodium tosylchloramide [INCI: chloramine T], chloroacetamide, p -chloro-m-cresol, 2-benzyl-4-chlorophenol [INCI: chlorophen], dimethyl oxazolidine, phenodethyl ammonium dodecyl-2bromide [INCI: domifene bromide], 7ethyl bicyclooxazolidine, hexetidine, glutaraldehyde, N- (4cl) -N- [4-chloro-3- (trifluoromethyl) phenyl] -urea [INCI: cloflucarban], 2-hydroxy-4-isopropyl-2,4,6-cycloheptatriene-
1-one [INCI: Hinokitiol], isopropylmethylphenol, mercury salts, aluminum salts, nisin, phenoxyisopropanol, ofenylphenol, 3-heptyl-2 - [(3-heptyl-4-methyl-3Hthiazol-2-ylidene) methyl ] -4-methylthiazole [INCI: Quaternium-73], silver chloride, sodium iodide, thymol, undecylenic acid, diethylene triamminapentacetic acid, ethylenediamine tetraacetic acid and ethylenediamine tetraacetates, lactoperoxidase, glucose oxidase, lactofenates, phenolates, acetates mercury and / or mixtures thereof, benzamidines, isothiazolines,
38/67 phthalimide derivatives, pyridine derivatives, guanidines, quinolines, 1,2-dibromo-2,4-dicyanobutane, iodine carbamate
2-propylbutyl, iodine, tamed iodines, peroxo compounds, 4chloro-3,5-dimethylphenol, 2,2'-methylene-bis (6-bromo-4-chlorophenol), 3-methyl-4- (1-methylethyl) phenol, 3- (4-chlorophenoxy) 1,2-propanediol, 3,4,4'-trichlorocarbanilide (TTC), thiamine essence, eugenol, farnesol, glycerin monolaurate, diglycerin monocaprinate, N-alkyl salicylic acid amide as n-octyl salicylic acid amide or n-decyl salicylic acid amide, halogenated xylene derivatives and cresol, such as p-chloro-meta-cresol or p-chloromethane-xylene, extracts of Allium sativum, Calendula officinalis, Chamomilla recutita , Echinacea Purpura, Hyssopus Officinalis, Melaleuca alternifolia or tea tree oil, clove essence, menthol and mint essence, among others.
Likewise, in another particular modality, the NO synthase inhibiting agent is selected, for example and not restricted to, from the group formed by extracts from the plants Vítís vinífera, Olea europaea or Gíngko bíloba, among others.
In a particular embodiment, the peeling agent and / or keratolytic agent and / or exfoliating agent is selected, for example and not restricted to, from the group formed by hydroxy acids and derivatives thereof, α-hydroxy acids, in particular, salicylic acid and derivatives thereof, or gentisic acid; β-hydroxy acids and their salts, such as glycolic acid, ammonium glycolate, lactic acid, 2-hydroxyoctanoic acid, α-hydroxycaprylic acid, mandelic acid, citric acid, malic acid or tartaric acid; α and β-hydroxybutyric acids; polyhydroxy acids such as gluconic acid, glucuronic acid or saccharic acid; keto acids like pyruvic acid, glyoxylic acid; pyrrolidinecarboxylic acid; cystic acid and derivatives; acids
39/67 aldobionics; azelaic acid and derivatives thereof such as azeloyl diglycinate; ascorbic acid and derivatives thereof such as 6-O-palmitoylascorbic acid, ascorbyl glycoside, dipalmitoylascorbic acid, magnesium salt of ascorbic acid-2-phosphate (MAP), ascorbic acid-2-phosphate sodium salt (NAP), ascorbyl tetraisopalmitate (IPCIP ); nicotinic acid, its esters and nicotinamide (also called vitamin B3 or vitamin PP); nordihydroguaiarético acid; urea; oligofucoses; cinnamic acid; derivatives of jasmonic acid; hydroxy stilbenes such as resveratrol; Saccarum officinarum extract; enzymes involved in the desquamation or degradation of corneodesmosomes, such as glycosidases, corneal layer chemotriptic enzyme (SCCE) or other proteases such as trypsin, chymotrypsin, sutilain, papain or bromelain; chelating agents such as ethylene diaminetetraacetic acid (EDTA) and its salts, aminosulfonic compounds such as 4- (2-hydroxyethyl) piperazine-1ethanesulfonic acid (HEPES) or sodium methylglycine diacetate (TRILON® M marketed by BASE); 2oxothiazolidine-4-carboxylic acid derivatives (procysteine); sugar derivatives like O-octanoyl-6-D-maltose and N-acetylglucosamine; pine nut extract (Castanea satíva) such as that marketed by SILAB under the name Recoverine® [INC1: water (Aqua), Castanea sativa Seed Extract]; opuntia extract (Opuntia ficus-indica) such as that marketed by SILAB as Exfolactive® [INC1: Opuntia Ficus Indica Hydrolyzate Flower Extract]; or Phytosphingosine SLC® [INCI: Saliciloil Fitosfingosina] sold by Degussa / Evonik, Peel-Moist [INCI: Glycerin, Papain, Calcium Pantothenate, Xanthan gum, Caprylyl Glycol, Urea, Magnesium Lactate, Ethylhexylglycerine, Lactate, Lactate, Lactate, Lactate, Alanine, Proline, Magnesium Chloride, Sodium Citrate]; extract or combination of extracts from Saphora japonica, papaya, pineapple,
40/67 pumpkin or sweet potato, and / or mixtures thereof.
In another particular modality, the anti-inflammatory agent and / or analgesic agent is selected, for example and not restricted to, from the group formed by madecassoside extract, echinacea extract, amaranth seed oil, sandalwood oil, leaf extract peach tree, Aloe vera extract, Arnica montana, Artemisia vulgaris, Asarum maximum, Calendula officinalis, Capsicum, Centipeda cunninghamii, Chamomilla recutita, Crinum asiaticum, Hamamelis virginiana, Harpagophytum procumbens, Hypericum perforatum, Origale ,umumumumumumumumumumumumumumumumum ,um majorana, Origanum vulgare, Prunus laurocerasus, Rosmarinus officialis, Salix alba, Silybum marianum, Tanacetum parthenium, Thymus vulgaris, Uncaria guianensis or Vaccinum myrtillus, mometasone furoate, prednisolone, non-steroidal anti-inflammatory drugs, lipid-lowering agents, lipid inhibitors, lipid inhibitors acetylsalicylic acid, rosmarinic acid, ursolic acid, glycyrrhizin derivatives ato, α-bisabolol, azulene and analogues, sericoside, ruscogenin, escin, scoline, rutin and analogues, hydrocortisone, clobetasol, dexamethasone, prednisone, paracetamol, amoxiprine, benorylate, choline salicylate, phislamine, methyl salicylate, methyl salicylate, salicylicate, methyl salicylate, salicylicate, methyl salicylate salsalate, diclofenac, aceclofenac, acemetacin, bromfenac, etodolac, indomethacin, oxamethacin, proglumetacin, sulindac, tolmetin, ibuprofen, dexibuprofen, carprofen, fenbufen, fenprofen, flurbiprofen, ketoprofen, ketoprofen, ketoprofen, ketoprofen, ketoprofen, ketoprofen, ketoprofen, thiaprofenic acid, suprofen, mefenamic acid, meclofenamate, meclofenamic acid, flufenamic acid, tolfenamic acid, nabumetone, phenylbutazone, azapropazone, clofezone, cebuzone, metamizole, mofebutazone, oxifenbutazone,
41/67 phenazone, sulfinpyrazone, piroxicam, lornoxicam, meloxicam, tenoxicam, celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib, nimesulide, naproxcinod, fluproquazone or licofelone, 6 oxycodone, hydrocodone, diamorphine, pethidine, tramadol, bupenorphine, benzocaine, lidocaine, chloroprocaine, tetracaine, procaine, amitriptyline, carbamazepine, gabapentin, pregabalin, bisabolol, Neutrazen ™ [INCI: Water, Butylene Glycol, Dextrane] by Atrium Innovations / Unipex Group, Meliprene® [INCI: Dextran, Acetyl Heptapeptide-1] marketed by Institut Europeen de Biologie Cellulaire / Unipex Group, Skinaserisyl ™ [INCI: Acetyl Tetrapeptideo-15] or Anasensyl ™ [INCI: Manitol, Ammonium Glicirr , Caffeine, Hippocastanum Extract (Horse Chestnut)] marketed by Laboratoires Serobiologiques / Cognis, Calmosensine ™ [INCI: Acetyl Dipeptide-1] marketed by Sederma, coenzyme Q10 or is alkylglycerin esters.
In addition, in another particular modality, the skin bleaching or depigmentation agent is selected, for example and not restricted to, from the group formed by extracts of Achillea millefolium, Aloe vera, Aradirachta indica, Asmuna japonica, Autocarpus incisus, Bidens pilosa, Broussonetia papyri fera, Chlorella vulgaris, Cimicifuga racemosa, Emblica officinalis, Glycyrrhiza glabra, Glycyrrhiza uralensis, Ilex purpureia, Ligusticum lucidum, Ligusticum wallichii, Ligusticum wallichi, Morinda citrifolia, Morinda citrifolia, , Rumex crispus, Rumex occidentalis, Sapindus mukurossi, Saxifragia sarmentosa, Scutellaria Galericulate, Sedum sarmentosum Bunge, Stellaria medica, Triticum Vulgare, Uva ursi or
42/67
Whitania somnifera, flavonoids, soy extract, lemon extract, orange extract, ginkgo extract, cucumber extract, geranium extract, gaiuba extract, locust bean extract, cinnamon extract, marjoram extract, rosemary extract, extract clove extract, soluble liquorice extract or blackberry leaf extract, Lipocroman-6 [INCI: Dimethylmethoxy Cromanol] or Chromabright ™ [INCI: Dimethylmethoxy Cromanyl Palmitate] marketed by Lipotec, Actiwhite ™ LS9808 [INCI: Water, Glicina Sucrose Dilaurate, Polysorbate 20, Pisum sativum (Pea) extract] or Dermawhite® NF LS9410 [INCI: Mannitol, Arginine HCI, Phenylalanine, Disodium EDTA, Sodium Citrate, Kojic Acid, Citric Acid, Commercial Yeast Extract] Serobiologiques / Cognis, Lumiskin ™ [INCI: Caprylic / Capric Triglyceride, Diacetyl-Boldine], Melaclear ™ [INCI: Glycerin, Water, Dithiaoctanediol, Gluconic acid, Sutilaines, Beta-carotene], ODAwhite ™ [INCI: octadecen acid dioic] or Etioline ™ [INCI: Glycerin, Butylene Glycol, Arctostaphylos uva ursi leaf extract, Mitracarpus scaber Extract] marketed by Sederma, Sepiwhite ™ MSH [INCI: Undecyleneil Phenylalanine] marketed by Seppic, Achromaxyl [INCI: Brassica napus] marketed by Vincience, Gigawhite ™ [INCI: Water, Glycerin, Malva sylvestris Extract (Malva), Mentha piperita Leaf Extract, Primula veris Extract, Alchemilla vulgaris Extract, Veronica officinalis Extract, Leaf Extract Melissa officinalis, Achillea millefolium Extract], Melawhite® [INCI: Leukocyte Extract, AHA] or Melfade®-J [INCI: Water, Arctostaphylos Leaf Extract uva-ursi, Glycerin, Ascorbyl Magnesium Phosphate] marketed by Pentapharm , Albatin® [INCI: Aminoethylphosphoric Acid, Butylene Glycol, Water] sold by Exsymol, Tyrostat ™ -! 1 [INCI: Water,
43/67
Glycerin, Rumex occidentalis Extract] or Melanostatine®-5 [INCI: Dextran, Nonapeptide-1] sold by Atrium Innovations, arbutin and its isomers, kojic acid and derivatives thereof, ascorbic acid and derivatives thereof such as 6-O- palmitoylascorbic, ascorbyl glycoside, dipalmitoylascorbic acid, magnesium salt of ascorbic acid-2-phosphate (MAR), sodium salt of ascorbic acid-2-phosphate (NAP), ascorbyl glycoside or ascorbyl tetraisopalmitate (VCIP); retinol and derivatives thereof, including tretinoin and isotretinoin, idebenone, hydroxybenzoic acid and derivatives thereof, niacinamide, liquiritine, resorcinol and derivatives thereof, hydroquinone, a-tocopherol, β-tocopherol, azelaic acid, azeloyl diglycinate, resveratrol, linoleic acid , α-lipoic acid, dihydrolipoic acid, ahhydroxy acids, β-hydroxy acids, ellagic acid, ferulic acid, cinnamic acid, oleanolic acid, aloesin and its derivatives and / or serine protease inhibitors, for example and not restricted to, inhibitors of tryptase, trypsin or PAR-2, among others.
In another particular embodiment, the agent that stimulates melanin synthesis, the pro-pigmentation agent, the self-tanning agent and / or the melanocyte proliferation stimulating agent is selected, for example and not restricted to, from the group formed by extracts of Citrus Aurantium Dulcis Fruit, Coleus forskohlii, Coleus Esquirolii, Coleus Scutellariodes, Coleus Xanthanthus, Ballota nigra, Ballota lanata, Ballota suavelens, Marrubium cylleneum, Cistus creticus, Amphiachyris amoena, Asteria oharai, Otterihara, Otterihara Larix laricema, dihydroxyacetone and derivatives thereof, sugars, for example and not restricted to, erythrulose, melanin and derivatives thereof including melanin polymers and melanin derivatives with a low molecular weight
44/67 soluble in water, forskolin and derivatives thereof including deacetylforscoline and isoforscholine, tyrosine and derivatives thereof including acetyl tyrosine, oleyl tyrosine, 3-amino tyrosine and 3-nitrotyrosine, copper salts such as CuCl2, carotenoids, canthaxanthins, polymers of dihydroxyindole carboxylic acid, 3,4-dihydroxybenzoic acid, 3-amino-4hydroxybenzoic acid, aloin, emodine, alizarin, dihydroxyphenylalanine, 4,5-dihydroxinaphthalenes-2sulfonic acid, 3-dimethylaminophenol or β-aminobenzoic acid, Melatime ™ Tripeptide-40] sold by Lipotec, Heliostatine IS ™ [INCI: Pisum Sativum Extract] sold by Vincience / ISP, Vegetan [INCI: Dihydroxyacetone] or Vegetan Premium [INCI: Dihydroxyacetone, Melanin] sold by Soliance, MelanoBronze [INCI: Extract Vitex Agnus Castus, Acetyl Tyrosine] sold by Mibelle Biochemistry, Melitane® [INCI: Acetyl Hexapeptide-1] sold by Institut Europeen de Biologie Cellulaire / Unipex Inn ovations, Actibronze® [INCI: Hydrolyzed Wheat Protein, Acetyl Tyrosine, Copper Gluconate] or Instabronze® [INCI: Dihydroxyacetone, Tyrosine] marketed by Alban Muller, Thalitan [INCI: Hydrolyzed Algine, Magnesium Sulphate, Manganese Sulfate] marketed by CODIF, Tyrosilane® [INCI: Methylsilanol Acetiltyrosine] marketed by Exsymol, Tyr-Excel ™ [INCI: Oleoil Tyrosine, Luffa Seed Oil Cylindrica, Oleic Acid] or Tyr-OI [INCI: Oleoil Tyrosine, Butylene glycol, Oleic acid ] marketed by Sederma / Croda, Bronzing SF
[Proposed INCI: Butyryl Pentapeptide] sold by Infinitec Activos or Biotanning® [INCI: Extract of Citrus Aurantium Dulcis Fruit Hydrolyzed] sold by Silab, among others.
In a particular modality, the anti-wrinkle and / or anti-aging agent is selected, for example and not
45/67 restricted to, from the group formed by extracts of Vitis vinifera, Rosa canina, Curcuma longa, Iris pallida, Theobroma cacao, Ginkgo biloba, Leontopodium Alpinum or Dunaliella salina, Matrixyl® [INCI: Palmitoil Pentapeptideo-4], Matrixil 3000® [INCI: Palmitoil Tetrapeptide-7, Palmitoil Oligopeptide], Essenskin ™ [INCI: hydroxymethrin calcium], Renovage [INCI: teprenone] or Dermaxyl® [INCI: Palmitoil Oligopeptide] marketed by Sederma, Vialox® [INCI: Pentapeptide-3 ], Syn®-Ake® [INCI: Dipeptide Diaminobutyryl Benzylamide Diacetate], Syn®-Coll [INCI: Palmitoil Tripeptide-5], Fitaluronate [INCI: Algorrobo Gum (Ceratonia Siliqua)] or Preregen® [INCI: Soy Protein (Soybean) Glycine, Oxide Reductases] marketed by Pentapharm / DSM, Myoxinol ™ [INCI: Hibiscus Esculentus Hydrolyzate Extract], Syniorage ™ [INCI: Acetyl Tetrapeptide-11], Dermican ™ [INCI: Acetyl Tetrapeptide-9] or DN-AGE ™ LS [INCI: Cassia Alata leaf extract] marketed by Labora toires Serobiologiques / Cognis, Algisum C® [INCI: Methylsilanol Manuronate] or Hydroxyprolisilane CN® [INCI: Methylsilanol Hydroxyproline Aspartate] marketed by Exsymol, Argireline® [INCI: Acetyl Hexapeptide-8], SNAP-7 [INCI: Acetyl Hepta] SNAP-8 [INCI: Acetyl Octapeptide-3], Leuphasyl® [INCI: Pentapeptide-18], Aldenine® [INCI: Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-1], Preventhelia® [INCI: Diaminopropionoil Tripeptide- 33], Decorinyl ™ [INCI: Tripeptide-10 Citrulline], Trylagen® [INCI: Pseudoalteromone Yeast Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline, Tripeptide-1], Eyeseryl® [INCI: Acetyl Tetrapeptide-5], Peptide AC29 [INCI: Acetyl Tripeptide-30 Citrulline], Lipocroman-6 [INCI: Dimethylmethoxy Chromanol], Chromabright ™ [INCI: Dimethylmethoxy Chromanyl Palmitate],
46/67
Antarcticine® [INCI: Pseudoalteromone Yeast Extract], Vilastene ™ [INCI: Lysine HCI, Lecithin, Tripeptide-10 Citrulline], dGlyage ™ [INCI: Lysine HCI, Lecithin, Tripeptide-9 Citrulline], Relistase ™ [INCI: Acetylsylate] Diphenylglycine] or Inyline ™ [INCI: Acetyl Hexapeptide-30] sold by Lipotec, Kollaren® [INCI: Tripeptideo-1, Dextran] sold by Institut Europeen de Biologie Cellulaire, Collaxyl® IS [INCI: Hexapeptideo-9], Laminixyl IS ™ [INCI: Heptapeptideo], Orsirtine ™ GL [INCI: Oryza Sativa Extract (Rice)], D'Orientine ™ IS [INCI: Phoenix Dactylifera Seed Extract (Date)], Phytoquintescine ™ [INCI: Einkorn Extract (Triticum Monococcum)] or Quintescine ™ IS [INCI: Dipeptideo-4] marketed by Vincience / ISP, BONT-LPeptideo [INCI: Palmitoil Hexapeptideo-19] marketed by Infinitec Activos, Deepaline ™ PVB [INCI: Palmitoil hydrolyzed wheat protein] or Sepilift ® DPHP [INCI: Dipalmitoil Hidroxiprolina] marketed by Seppic , Gatuline® Expression [INCI: Acmella oleracea Extract], Gatuline® InTense [INCI: Spilanthes Acmella Flower Extract] or Gatuline® Age Defense 2 [INCI: Juglans Regia Seed Extract (Walnut)] marketed by Gattefosse, Thalassine ™ [INCI: Seaweed Extract] marketed by Biotechmarine, ChroNOIine ™ [INCI: Caprooil Tetrapeptide-3] or Timulen-4 [INCI: Acetyl Tetrapeptide-2] marketed by Atrium Innovations / Unipex Group, EquiStat [INCI: Fruit Extract from Pyrus Malus, Glycine Soybean Extract] or Juvenesce [INCI: Etoxidiglycol and Caprylic Triglyceride, Retinol, Ursolic Acid, Phytonadione, llomastat] marketed by Coletica, Ameliox [INCI: Carnosine, Tocopherol, Silybum Malianto Extract] or Marilyum Fruit Extract] Domestica [INCI: Cell Culture of Malus Domestica Fruit] sold by ibelle Biochemistry, Bioxilift [INCI:
47/67
Pimpinella Anisum Extract] or SMS Anti-Wrinkle® [INCI: Annona Squamosa Seed Extract] marketed by Silab, Ca ²⁺ channel blockers, for example and not restricted to, alverine, manganese or magnesium salts, certain amines secondary or tertiary, retinol and derivatives thereof, resveratrol, idebenone, coenzyme Q10 and derivatives thereof, boswellic acid and derivatives thereof, GHK and derivatives thereof and / or salts, carnosine and derivatives thereof, DNA repair enzymes, for example and not restricted to, photoliase or T4 endonuclease V, or chloride channel blockers, among others.
In a particular embodiment, the lipolytic agent or agent that stimulates lipolysis, venotonic agent and / or anti-cellulite agent is selected, for example and not restricted to, from the group formed by extracts of Bupleurum Chinensis, Cecropia Obtusifolia, Celosia Cristata, Centella Asiatica , Chenopodium Quinoa, Chrysanthellum Indicum, Citrus Aurantium Amara, Coffea Arabica, Coleus Forskohlii, Commiphora Myrrha, Crithmum Maritimum, Eugenia Caryophyllus, Ginkgo Biloba, Hedera Helix (ivy extract), Hibiscus Sabdariaria, Ide, Cupana, Peumus Boldus, Phyllacantha Fibrosa, Prunella Vulgaris, Prunus Amygdalus Dulcis, Ruscus Aculeatus (Butcherbroom extract), Sambucus Nigra, Spirulina Platensis Algae, Uncaria Tomentosa or Verbena Officinalis, dihydromiracine, lipid, regina, ®-Shape [INCI: Isomerized Linoleic Acid, Lecithin, Glycerin, Polysorbate 80] sold by Pentapharm / DSM, UCPeptide ™ V [INCI: Pentapeptide] or AT Peptide ™ IS [INCI: Tripeptideo-3] marketed by Vincience / ISP, Liporeductyl® [INCI: Caffeine, Butcherbroom Root Extract (Ruscus Aculeatus), TEA-Hydroiod, Carnitine, Ivy Extract (Hedera Helix),
48/67
Escina, Tripeptideo-1] sold by Lipotec, Adiposlim [INCI: Sorbitan Laurate, Lauroil Prolina] sold by SEPPIC, caffeine, carnitine, escin and / or triethanolamine iodide, among others.
In a particular embodiment, the heat shock protein synthesis stimulating agent is selected, for example and not restricted to, from the group formed by extracts of Opuntia fícus indica, Salix alba, Luplnus spp. , Secale cereale, red seaweed extracts of the genus Porphyra, crustacean extracts of the genus Artemia, jojoba seed oil, grape seed extracts, green tea extracts, geranyl geranyl acetone, celastrol, zinc and its salts, 2cyclopenten-l-one , proteasome inhibitors, for example and not restricted to, bortezomib; prostaglandins and derivatives thereof, hydroxylamine and derivatives thereof, for example and not restricted to, bimoclomol; chalcone and derivatives thereof, hyperosmotic agents, for example and not restricted to, sorbitol and derivatives thereof, mannitol and derivatives thereof, or glycerol and derivatives thereof, isosorbide, urea or salicylic acid and derivatives thereof, among others, Thermostressine ™ [INCI: Acetyl Tetrapeptide-22], or mixtures thereof.
In another particular modality, the hair growth inducing agent, the agent that acts on the capillary circulation and / or microcirculation, or the hair loss retarding agent is selected, for example and not restricted to, from the group formed by the extracts of Tussllago farfara or Achillea millefolium, nicotinic acid esters such as C3-C6 alkyl nicotinates such as methyl or hexyl nicotinate, benzyl nicotinate, or tocopheryl nicotinate; biotin, 5a reductase inhibiting agents, anti-inflammatory agents, retinoids, for example and not restricted to, all-trans-retinoic acid or tretinoin, isotretinoin,
49/67 retinol or vitamin A, and derivatives thereof, such as zinc salt of acetate, palmitate, propionate, motretinide, etretinate and trans-retinoate; antibacterial agents, calcium channel blockers, for example and not restricted to, cinnarizine and diltiazem; hormones, for example and not restricted to, estriol, its analogs or thyroxine, its analogs and / or salts; antiandrogenic agents, for example and not restricted to, oxendolone, spironolactone or dietilstylbestrol; antiradical agents, esterified oligosaccharides, for example and not restricted to, those described in EP 0211610 and EP 0064012; derivatives of hexosaccharic acids, for example and not restricted to, glucosaccharic acid or those described in EP 0375388; glucosidase inhibitors, for example and not restricted to, D-glucaro-1,5-lactam or those described in EP 0334586; glycosaminoglycanase and proteoglycanase inhibitors, for example and not restricted to L-galactone-1,4-lactone or those described in EP 0277428; tyrosine kinase inhibitors, for example and not restricted to, 1-starch-1-cyano (3,4-dihydroxyphenyl) ethylene or those described in EP 0403238, diazoxides, for example and not restricted to, 7 (acetylthio) -4 ', 5'-dihydrospiro [androst-4-eno-17,2 '- (3H) furan] -
3-one, 3-methyl-7-chloro [2H] 1,1,2-dioxide-1,2,4-benzothiadiazine or spirooxazine; phospholipids, for example and not restricted to, lecithin; salicylic acid and derivatives thereof, hydroxycarboxylic or keto carboxylic acids and esters thereof, lactones and their salts; anthralin, eicosa-5,8,11-trienoic acids and esters thereof or amides among others, minoxidyl and derivatives or mixtures thereof.
In another particular embodiment, the hair growth retarding or inhibiting agent is selected, for example and not restricted to, from the group formed by activin or activin agonists, flavonoids as
50/67 quercetin, curcumin, galangin, fisetin, myricetin, apigenin; propyl gaiato, nordihydroguaiaretico acid, caffeic acid, tyrosine kinase inhibitors such as lavendustine, erbstatin, tirfostins, benzoquinone-ansamycin herbimycin A, thiazolidinediones, phenazocine, 2,3-dihydro-2-thioxolH-indol-3-alkanoic acids, phenothiazine derivatives as thioridazine; sphingosine and derivatives thereof, staurosporine and derivatives thereof, glycyrretinic acid, lauryl isoquinoline bromide, Decelerine ™ [INCI: Lauryl Isoquinoline bromide, Pseudoalteromone Yeast Extract] marketed by Lipotec or protease serine inhibitors, trypsin and / or mixtures of the same.
In a particular embodiment, the cosmetic and / or absorbent and / or deodorant masking body odor and / or antiperspirant, perfume substance and / or perfumed oil is selected, for example and not restricted to, from the group formed by the complex zinc salt of ricinoleic acid, Styrax, abiotic acid derivatives, sage essence, chamomile essence, clove essence, lemon balm essence, mint essence, cinnamon leaf essence, lime flower essence, juniper essence , essence of vetiver, essence of frankincense, essence of galbanum, essence of labdanium, essence of lavender, essence of mint, bergamot orange, dihydromyrcenol, lilial, liral, citronellol, lemon essence, mandarin essence, orange essence, essence of lavender, muscat, essence of bourbon geranium, anise seed, coriander, cumin, juniper, extracts of fleur-de-lis, lilac, roses, jasmine, lime flower; benzyl acetate, p-tertbutylcyclohexyl acetate, linalyl acetate, phenylethyl acetate, ethyl methylphenyl glycinate, linalyl benzoate, benzyl formate, allyl cyclohexyl propionate, styryl propionate, benzyl salicylate, benzyl ether
51/67 linear alkanes with 8 to 18 carbon atoms, citral, ricinoleic acid, citronelal, citronelil oxyacetaldehyde, cyclamen aldehyde, hydroxycitronelal, bourgeonal, ionones, methyl cedril ketone, anethole, eugenol, isoeugenol, geraniol, linalool, terylene , a-hexylcinamaldehyde, geraniol, benzylacetone, cyclamen aldehyde, ambroxan, indole, hedione, sandelice, cyclovertal, / 3-damascona, alii amyl glycolate, diidromyrcenol, phenoxyethyl isobutyrate, cyclohexyl salicylate, irisylacetic acid, phenylacetic acid floramato, active astringent products such as aluminum chloride, aluminum hydrochloride, aluminum dihydrochloride, aluminum sesquichlorohydrate, aluminum hydroxyalanthinate, aluminum chlorohydrate, aluminum and zirconium hydrochloride, aluminum and zirconium tetrachloride, and aluminum and zirconium pentachloride and / or mixtures thereof.
In a particular embodiment, the antioxidant is selected, for example and not restricted to, from the group formed by butylhydroxytoluene (BHT), butylhydroxyanisol (BHA), tert-butylhydroquinone (TBHQ), 2,6, -di-tert-butyl -4methylphenol, gallic acid esters such as propyl gallate, probucol, polyphenols, ascorbic acid and its salts, enzymes such as catalase, superoxide dismutase and peroxidases; citric acid, citrates, monoglyceride esters, calcium metabisulfate, lactic acid, malic acid, succinic acid, tartaric acid, vitamin A or β-carotene, vitamins E and C, tocopherols such as vitamin E acetate, ascorbic acid esters such as ascorbic acid palmitate ascorbyl and ascorbyl acetate, zinc, copper, mannitol, reduced glutathione, carotenoids such as cryptoxanthin, astaxanthin and lycopene; cysteine, uric acid, carnitine, taurine, tyrosine, lutein, zeaxanthin, N-acetylcysteine, carnosine, α-glutamylcysteine, quercetin, lactoferrin, dihydrolipoic acid, tea catechins,
52/67 retinyl palmitate and derivatives thereof, bisulfate, metabisulfide and sodium sulphide, chromans, chromenes and their analogs, Lipocroman-6 [INCI: Dimethylmethoxy Cromanol], metal chelating agents such as EDTA, sorbitol, phosphoric acid or dGlyage ™ [INCI: Lysine HCI, Lecithin, Tripeptide-9 Citrulline]; Ginkgo Biloba extract, plant extracts such as sage, pomegranate, rosemary, oregano, ginger, marjoram, blackberry, grape, tomato, green tea or black tea; oleoresin extract, plant extract containing phenols such as vanillin, ellagic acid and resveratrol; tertiary butylhydroquinone or mixtures thereof, metal salts with a valence of 2 such as selenium, cadmium, vanadium or zinc; α-lipoic acid, coenzyme Q, idebenone or derivatives thereof.
In a particular embodiment, the agent that inhibits sweat degradation enzymes is selected, for example and not restricted to, from the group formed by trialkyl citrates such as trimethyl citrate, tripropyl citrate, triisopropyl citrate, tributyl citrate or triethyl citrate; lanosterine sulfate or phosphate, cholesterin, campesterin, stigmasterine and sitosterine; dicarboxylic acids and their esters, such as glutaric acid, monoethyl glutarate, diethyl glutarate, adipic acid, monoethyl adipate, diethyl adipate; malonic acid and diethyl malonate, hydroxycarboxylic acids and their esters such as malic acid, tartaric acid or diethyl tartrate, zinc glycinate and / or mixtures thereof.
In another particular embodiment, the agent that has the ability to filter UV rays is selected, for example and not restricted to, from the group formed by organic photoprotective agents or minerals active against ultraviolet A and / or B rays such as substituted benzotriazoles, diphenylacrylates substituted, complexes of organic nickel, umbeliferone, urocanic acid, biphenyl derivatives,
53/67 stilbene, 3-benzylidene camphor, and derivatives thereof as
3- (4-methylbenzylidene) camphor; derivatives of 2-ethylhexyl 4- (dimethylamino) benzoate, 2-octyl 4- (dimethylamino) benzoate and amyl 4- (dimethylamino) benzoate; esters of cinnamic acid, such as 2-ethylhexyl 4-methoxycinnamate or diethylamino hydroxybenzoyl hexyl benzoate,
4- propyl methoxycinnamate, isoamyl 4-methoxycinnamate, 2-ethylhexyl cinnamate (octocrilenes) 2-cyano-3,3-phenyl; esters of salicylic acid, such as 2-ethylhexyl salicylate, 4-isopropylbenzyl salicylate, homomentyl salicylate; benzophenone derivatives, such as 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone; benzalmalonic acid esters, such as di-2-ethylhexyl 4-methoxybenzalmalonate; triazine derivatives, such as 2,4,6-trianilino, βcarbo-2 '-ethyl-1'-hexyloxy-1, 3,5-triazine, octyl triazone or dioctyl butamido triazones; propane-1,3-diones, such as 1— (4— tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione; derivatives of ketotriciclo (5.2.1.0) decane; 2-phenylbenzimidazole-5-sulfonic acid; derivatives of benzophenone sulfonic acid, such as 2-hydroxy-4-methoxybenzophenone-5 sulfonic acid and its salts; 4- (2-oxo-3bornylidenemethyl) benzenesulfonic acid, benzoyl methane derivatives, as benzoyl methane 2-methyl-5- (2-oxo-3bornylidene) sulfonic acid, as 1- (4'-tert-butylphenyl) -3- (4'methoxyphenyl) propane-1,3-diono, 4-tert-butyl-4 'methoxydibenzoylmethane, l-phenyl-3- (4'-isopropylphenyl) -propane1, 3-dione, enamine compounds, anthranilates, silicon, benzimidazole derivatives, imidazolines, benzoyl derivatives, Chromabright ™ [INCI: Dimethylmethoxy Cromanyl Palmitate] or Preventhelia® [INCI: Diaminopropionoil Tripeptideo-33] both marketed by Lipotec, metal oxides such as zinc oxide, titanium, iron, zirconium, zirconium ,
54/67 manganese, aluminum and cerium; silicates, talc, barium sulfate, zinc stearate, carbon nanotubes and / or mixtures thereof.
In addition, in another particular modality, the agent that stimulates or regulates keratinocyte differentiation is selected, for example and not restricted to, from the group formed by minerals like calcium, retinoids like retinol or tretinoin, analogues of vitamin D3 like calcitriol , calcipotriol or tacalcitol, lupine (Lupinus albus) extract such as that marketed by SILAB under the name Structurin® [INCI: Hydrolyzed Lupine Protein], / ^ - sitosterol sulfate, such as that marketed by Vincience / ISP under the name Phytocohesine PSP® [INCI: Beta-sitosterol sulphate Sodium], plus (Zea Mays) extract like that marketed by Solabia under the name Phytovityl C® [INCI: water (water), Green Corn Extract (Zea Mays)], glycoconjugates of Helix Aspersa Muller and / or mixtures thereof.
Likewise, in another particular modality, the muscle relaxant, the agent that inhibits muscle concentration, the agent that inhibits the acetylcholine receptor group and / or the anticholinergic agent is selected, for example and not restricted to, from the group formed by extracts of Atropa belladonna, Hyoscyamus niger, Mandragora officinaruin, Chondodendron tomentosum, plants of the genus Brugmansía, or of the genus Datura, toxin of Clostridium botulinum, peptides derived from the protein SNAP-25 or Inyline ™ [INCI: Acetyl Hexapeptide-30] marketed by Lipotec, baclofen, carbidopa, levodopa, bromocriptine, chlorphenesine, chlorzoxazone, donepezil, mefenoxalone, reserpine, tetrabenazine, dantrolene, thiocolchicoside, tizanidine, clonidine, prociclidine, glycopyrroline, atropine, atropine, atropine, atropine
55/67 promethazine, diphenhydramine, dimenhydrinate, dicyclomine, cyclobenzaprine, orphenadrine, flavoxate, cyclopentolate, ipratropium, oxybutynin, pirenzepine, tiotropium, trihexiphenidine, tolterodine, tropicamide, solifenacurio, trifoxacine, atrifenacine, darifenacine, atrifenacine, darifenacine mivacurium, pancuronium, pipecuronium, rapacuronium, tubocuranine, dimethyl tubocuranine, rocuronium, vecuronium, suxamethonium, 18methoxycoronaridine, carisoprodol, febarbamate, meprobamate, metocarbamol, fenprobamate, tbamate, tibamate, antitubbate, tibamate, agents pyrimidone, carbamazepine, oxcarbazepine, benzodiazepines, for example and not restricted to, clonazepam, cloxazolam, chlorazepate, diazepam, flutoprazepam, lorazepam, midazolam, nitrazepam, nimetazepam, fenazepam, temazepam, temazepam, tmazepam, or
In another particular embodiment, the nanocapsules of the present invention comprise other active ingredients and / or pharmaceutical adjuvants of any kind, hydrophobic, hydrophilic or amphiphilic, which can be found inside the nanocapsules in solution or in suspension in the lipid matrix, or in the aqueous phase of the microemulsion. In particular, the active ingredients and / or pharmaceutical adjuvants are selected, for example and not restricted to, from the group formed by antacids, agents against peptic ulcers and gastroesophageal reflux disease, antispasmodics, analgesics, anticholinergic drugs, propulsive drugs, antiemetics , anti-nausea drugs, agents for biliary therapy, agents for liver therapy, lipotropics, laxatives, antidiarrheals, intestinal adsorbents, anti-propellants, anti-inflammatory drugs, active ingredients against obesity, enzymes, hypoglycemic drugs,
56/67 insulin and analogues, vitamins, proteins, minerals, anabolic steroids, antithrombotic agents, antifibrinolytics, hemostatic agents, antiarrhythmic agents, cardiac stimulants, cardiac glycosides, vasodilators, antiadrenergic agents, antihypertensive drugs, diuretics, potassium-saving agents , anti-hemorrhoids, anti-viral therapy agents, capillary stabilizing agents, agents that act on the renin-angiotensin system, beta-blockers, selective calcium channel blockers, non-selective calcium channel blockers, ACE inhibitors, angiotensin II inhibitors , lipid modifying agents, antifungals, healing agents, antipruritics, antihistamines, anesthetics, antipsoriatics, chemotherapy drugs, corticosteroids, antiseptics, disinfectants, anti-acne agents, products for gynecological use, oxytocics, contraceptives, androgen, estrogen, stimulants, estrogen, progestogen ovulation, gonadotropins, antiandrogens, products for urological use, antispasmodics, drugs used in benign prostatic hypertrophy, hormones, hormone antagonists, antibiotics, tetracyclines, amphenicols, beta-lactam antibacterials, penicillin, sulfonamides, trimethoprim, macrolides, lincosamines, streptoines , antivirals, immune serum, immunoglobulins, antineoplastic agents, immunomodulatory agents, alkylating agents, antimetabolites, plant alkaloids and other natural products, cytotoxic antibiotics, immunosuppressive agents, drugs for skeletal muscle system disorders, antirheumatic agents, muscle relaxants, agents that affect bone structure and mineralization, drugs that act on the nervous system, general anesthetics, local anesthetics, opioids, agents
57/67 antimigraine, anticonvulsants, cholinergic agents, dopaminergic agents, antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants, psychostimulants, antidementia drugs, parasympathomimetics, drugs used in additive disorders, antivarizing agents, antiparasitic agents, insecticides, insecticides, insecticides , mucolytic agents, cough suppressants, ophthalmic active ingredients, otological active ingredients, antiglaucoma drugs, myotics, mydriatics, cycloplegics and / or mixtures thereof.
In another particular embodiment, the nanocapsules of the present invention that contain active ingredients and / or cosmetic and / or pharmaceutical adjuvants can be incorporated into natural or synthetic fibers of textile materials before or after their manufacture. In this invention, it is understood that textile materials are woven fabrics, non-woven fabrics, suits and medical devices. These textile materials, in direct contact with the skin of the body, release the active ingredients incorporated into the delivery system of the present invention by biodegradation of the binding system to the tissue fabric, non-woven fabric or medical device or due to friction between the themselves and the body, due to body moisture, skin pH or body temperature. Examples of woven fabrics, non-woven fabrics, suits, medical devices and means for immobilizing delivery systems can be found in the prior art (J. Cont. Release 2004, 97, 313 to 320). Means for immobilizing delivery systems in preferred textile materials are application by means of a foulard, exhaustion bath or spray. Natural and / or synthetic fibers can be wool, cotton, silk, nylon fibers, cellulose, polyamide or polyester, among others. Among textile materials, woven fabrics, non-woven fabrics
58/67 preferred fabrics, suits and medical devices are bandages, gauze, shirts, socks, tight pants, underwear, corsets, gloves, diapers, absorbents, dresses, sheets, scarves, hydrogels, adhesive plasters, non-adhesive plasters, microelectric plasters and / or face masks.
According to another aspect, this invention relates to a cosmetic, pharmaceutical and / or food composition comprising the nanocapsules of the present invention.
The nanocapsules of the present invention can also be adsorbed on solid organic polymers or solid mineral supports, for example, and not restricted to, talc, bentonite, silica, starch or maltodextrin, among others.
The nanocapsules of the present invention can be incorporated into any form of functional food or enriched food or in oral or nutricosmetic cosmetics and formulated with the usual excipients and adjuvants for oral compositions or food supplements, for example, and not restricted to, fatty components, components aqueous, humectants, preservatives, texturing, flavoring, flavors, antioxidants and food coloring agents commonly used in the food industry.
Cosmetic, pharmaceutical and / or food compositions comprising the nanocapsules of the present invention can be prepared by conventional methods known to those skilled in the art. The cosmetic, pharmaceutical and / or food compositions that incorporate the nanocapsules of the present invention can be a final composition, available for application without having to perform any type of concentration, solution, dilution, dispersion, spray, spray or any other similar procedure known by the versed in
59/67 technique, or an intermediate composition for which one or several of the previous procedures will be performed or any other procedure known to the person skilled in the art for the purpose of obtaining a final composition.
Cosmetic, pharmaceutical and / or food compositions comprising the nanocapsules of the present invention can be administered by topical or transdermal administration, orally, or by any other suitable route, for example, parenteral, and the cosmetic and / or pharmaceutically acceptable excipients necessary to formulate the desired method of administration will be included. In the context of the present invention, the term parenteral includes nasal routes, headset, ophthalmic, rectal, urethral and vaginal, subcutaneous injections, intradermal, intravascular, such as intravenous, intramuscular, intraocular, intravitreal, intracorneal, intraspinal, intramedullary, intracranial, intracervical, intracranial , intramenineal, intraarticular, intrahepatic, intrathoracic, intratracheal, intrathecal and intraperitoneal, as well as any other similar infusion or injection techniques.
The cosmetic and / or pharmaceutical compositions comprising the nanocapsules of the present invention can be used in different types of topically and transdermally applied compositions which, optionally, will include the cosmetic and / or pharmaceutically acceptable excipients necessary for formulating the desired method of administration . Compositions for topical or transdermal application can be presented in any solid, liquid or semi-solid formulation, for example, and not restricted to creams, multiple emulsions, for example, and not restricted to, oil and / or silicone in water emulsions, water in oil and / or silicone emulsions, water / oil / water type emulsions or
60/67 water / silicone / water, and oil / water / oil or silicone / water / silicone emulsions, anhydrous compositions, aqueous dispersions, oils, milks, balms, foams, lotions, gels, cream gels, hydroalcoholic solutions, solutions hydroglycolic, hydrogels, liniments, serums, soaps, shampoos, conditioners, serums, polysaccharide films, ointments, mousses, ointments, powders, bars, pencils and sprinklers or aerosols, including formulations with or without rinsing. These topical and transdermal formulations can be incorporated by techniques known to those skilled in the art in different types of solid accessories, for example, and not restricted to, bandages, gauze, shirts, socks, tights, underwear, straps, gloves , diapers, sanitary napkins, dressings, bedspreads, wipes, adhesive patches, non-adhesive patches, microelectric patches or facial masks, or can be incorporated into different makeup products as a makeup base, for example, fluid foundations and compact foundations, lotions makeup removal, makeup removal milks, eye concealers, shadows, lipsticks, lip balms, glossy lipsticks and powders, among others. The cosmetic or dermopharmaceutical compositions of the present invention can also be incorporated into products for the treatment and / or care of nails and cuticles such as nail varnishes, lotions to remove nail varnish and lotions to remove nail varnish, among others.
Cosmetic, pharmaceutical and / or food compositions comprising the nanocapsules of the present invention can be used in different types of formulations for oral administration, preferably in the form of cosmetics or oral drugs, for example, and not restricted to, capsules, including gelatin capsules, soft capsules, hard capsules, tablets, including sugar tablets
61/67 coated, powders, granules, chewing gum, solutions, suspensions, emulsions, syrups, polysaccharide films, jellies or gelatines and any other form known to the person skilled in the art.
In another particular embodiment, the compositions comprising the nanocapsules of the present invention can be used for the treatment of textile materials and can be found in washing agents in liquid form, as well as detergents, in the manufacture of emulsions, rinse aid, cleaning agents rinse, fabric softeners, sprinklers, liquid soaps or gels or also in solid form, such as powders, granules or compacts. In addition, these compositions contain other components, for example, and not restricted to, surfactants, agents that increase percutaneous absorption, agents for the pretreatment of textile materials, agents for the treatment of marks, abrasives, water softeners, fabric softeners fabrics, solvents or solubilizing agents, agents for the variation of touch and finish, dirt repellent agents, antistatic agents, enzymes, agents that assist in the passage of ruptures, bleaching and / or coloring agents, glossing agents, optical bleaching agents , graying inhibitors or compounds for releasing dirt, color transfer inhibitors, phobizing and impregnating agents, swelling or thickening agents, consistency-generating agents, silicon agents, agents that increase percutaneous absorption of microcapsules, agents bleaching and bleaching activators of textile material, hydrophilizing agents and / or mixtures thereof.
Another aspect of the present invention relates to the use of cosmetic, pharmaceutical and / or food compositions that comprise the nanocapsules of the present invention for the
62/67 treatment and / or care of skin, scalp, hair and nails. Preferably, the treatment and / or care of the skin, hair, scalp and / or nails is selected from the group formed by treatment and / or prevention of skin aging, healing of the skin and / or scalp, dermatological treatment of diseases of the skin. skin, cellulite treatment and / or prevention, skin tanning, skin whitening or bleaching and treatment and / or hair loss prevention. In the context of the present invention, the term aging refers to changes experienced by the skin with age (chronoaging) or due to exposure to the sun (photoaging) or environmental agents such as cigarette smoke, extreme cold or windy conditions, chemical pollutants or pollution, and includes all visible external changes, as well as those noticeable by touch, for example, and not restricted to, the development of discontinuities in the skin such as wrinkles, fine expression lines, furrows, irregularities or roughness, increase in the size of pores, loss of elasticity, loss of firmness, loss of softness, loss of the ability to recover from deformation, sagging skin such as sagging cheeks, the appearance of bags under the eyes or the appearance of a double chin, among others, changes in color of skin such as marks, redness, bags under the eyes, appearance of hyperpigmented areas such as spots on the skin or freckles, among others, anomalous differentiation, hyperkeratinization, elastosis, keratosis, hair loss, orange peel skin, loss of collagen structure and other histological changes in the corneal layer, dermis, epidermis, vascular system (for example, the appearance of spider veins or telangiectasias) or tissues close to the skin, among others.
Another aspect of the present invention relates to the use of cosmetic, pharmaceutical and / or food compositions that
63/67 contain the nanocapsules of the present invention for the treatment of textile materials.
The specific examples given below serve to illustrate the nature of the present invention. These examples are included for illustrative purposes only and should not be construed as limitations on the invention claimed here.
EXAMPLES
GENERAL METHODOLOGY
All reagents and solvents are of synthetic quality and are used without further treatment.
The high pressure homogenizations were performed in a microfluidizer model Ml 10-Y from Microfluidics. The Ultraturrax mixer for the formation of microemulsions is the D-8 model from Miccra RT.
The hydrophilic thermolabile peptides in the form of microemulsion were nanoencapsulated by means of complex coacervation. The lipid matrix of the nanocapsules contained only lipids or liquid oils, so it was not necessary to apply heat during the entire process and the degradation of the peptides was avoided.
EXAMPLE 1
Preparation of hydrophilic peptide microemulsions for subsequent encapsulation in coacervate nanocapsules containing liquid lipids.
Example 1-a. Microemulsion of the H-Dpr-AlaAsn-His-QH peptide
Ducosate [INCI: DIETYL-HEXIL SULFOSUCCINATE SODIUM] and isostearic acid [INCI: ISOSTEARIC ACID] (phase A) were mixed together in a suitable container. In another container, the H-Dpr-Ala-Asn-His-OH peptide was dissolved in ethanol [INCI: ALCOHOL]. Once dissolved, water was added (phase B).
64/67 agitation.
Phase B was added to phase A slowly under
INGREDIENT (INCI Nomenclature) % BY WEIGHT SODIUM DIETHYL-HEXIL SULPHOSUCCINATE / 89, 75 ISOSTEARIC ACID (15/85) B H-Dpr-Ala-Asn-His-OH 0.25 B Water (AQUA) 7.00 B ALCOHOL 3.00
Example 1-b. Microemulsion of the peptide Ac-Arg-AsnHls-Clt-NH ₂
Ducosate [INCI: DIETYL-HEXYL SODIUM SULPHOSUCCINATE] and isostearic acid [INCI: ISOSTEARIC ACID] (phase A) were mixed together in a suitable container.
In another container, the peptide Ac-Arg-Asn-His-CitNH2 was dissolved in water. Once dissolved, ethanol [INCI: ALCOHOL] (phase B) was added.
Phase B was added to phase A slowly with stirring.
INGREDIENT (INCI Nomenclature) % BY WEIGHT SODIUM DIETHYL-HEXIL SULPHOSUCCINATE / 89, 84 ISOESTEARIC ACID (15/85) B Ac-Arg-Asn-His-Cit-NH2 0.16 B Water (AQUA) 4.00 B ALCOHOL 6.00
EXAMPLE 2
Preparation of nanocapsules coacervated with peptides hydrophilic microemulsified containing only lipids liquids.In a container appropriate, next were added in that order: water, friend [INCI: GUM
SCLEROTIC], hyaluronic acid [INCI: SODIUM HYALURONATE],
Zemea [INCI: PROPANODIOL] and phenoxyethanol [INCI: FENOXIETANOL]
65/67 (ingredients A), and the mixture was stirred until homogeneity was achieved.
In another container, the microemulsion of the corresponding peptide prepared according to example 1, soybean oil [INCI: SOYBEAN SOYBEAN (GLYCINE SOYBEAN)], Arlacel 83 [INCI: SORBITAN SESQUIOLEATE] and Arlamol HD [ INCI: ISOHEXADECANO] (ingredients B) were mixed.
Then, the mixture of ingredients B was added to the mixture of ingredients A, under stirring with the turbine until the emulsion was formed.
Finally, the mixture was homogenized under pressure in a microfluidizer for 3 cycles with an inlet pressure of 80 bar and an outlet pressure of 15,000 psi. Throughout the process, the sample was maintained at 25 ° C by means of a refrigerated water / glycol circuit.
Then, a suspension of Quat Soy LDMA 25 [INCI: HYDROXYPROPYL HYDROLYZED SOY PROTEIN] (ingredients C) in water was added by dripping with stirring.
For the H-Dpr-Ala-Asn-His-OH peptide, the microemulsion prepared according to example 1-a was used.
INGREDIENT (INCI Nomenclature) % BY WEIGHT Water (AQUA) QSP100 THE SCLEROTIC GUM 0.50 PROPANODIOL 5.00 PHENOXYETHANOL 2, 6 SODIUM HYALURONATE 0.01 B H-Dpr-Ala-Asn-His-OH, DIETIL-HEXILSODIUM / ACID SULPHOSUCCINATEISOSTEARIC (15/85), 8.00 Water (AQUA), ALCOHOLB GLYCINE SOYBEAN (SOYBEAN) 12.00
66/67
B SORBITAN SESQUIOLEATE 4.30 B ISOHEXADECANO 5, 50 C Water (AQUA) 2.00 C HYDROLYZED SOY PROTEINOF LAURILDIMÔNIO HIDROXIPROPIL 0.20
average size of the obtained suspension capsules, containing the H-Dpr-Ala-Asn-His-OH peptide and determined by Dynamic Laser Light Scattering, was 235 nm.
For the peptide Ac-Arg-Asn-His-Cit-NH2, the microemulsion prepared according to example 1-b was used.
INGREDIENT (INCI Nomenclature) % BY WEIGHT Water (AQUA) QSP100 THE SCLEROTIC GUM 0.50 PROPANODIOL 5.00 PHENOXYETHANOL 2, 6 SODIUM HYALURONATE 0.01 B Ac-Arg-Asn-His-Cit-NH ₂ , DIETIL-HEXILSODIUM / ACID SULPHOSUCCINATE 10.00 ISOSTEARIC (15/85), Water (AQUA), ALCOHOLB GLYCINE SOYBEAN (SOYBEAN) 10.00 B SORBITAN SESQUIOLEATE 6.50 B ISOHEXADECANO 3.00 C Water (AQUA) 2.00 C HYDROLYZED SOY PROTEIN 0.20 LAURILDIMÔNIO HIDROXIPROPIL
average size of the obtained suspension capsules, containing the peptide Ac-Arg-Asn-His-Cit-NH2 and determined by Dynamic Laser Light Scattering, was 303 nm.
In the encapsulation of peptides, the separation of the encapsulated and non-encapsulated active ingredient was performed by the basket centrifugation technique [David W. Fry et al. Analytical Biochemistry 90: 809 to 815 (1978)]. Once both fractions have been separated, the pate will not
Encapsulated 67/67 was analyzed by HPLC. In no case was the presence of peptide detected in the aqueous phase of the dispersion, therefore, the encapsulation efficiency was almost 100%.

权利要求:
Claims (5)
[1]
1. POLYMERICALLY COATED NANOCASULES, characterized by the fact that they contain microemulsions of water in liquid lipids and that comprise at least one
5 hydrophilically active ingredient dissolved in the internal aqueous phase and where the polymeric coating is a complex coacervate.
[2]
2. NANOCAPPSULES, according to claim 1, characterized in that liquid lipids are selected • 10 from the group formed by vegetable oils, soybean oil, sunflower oil, corn oil, olive oil, palm oil, cottonseed oil, rapeseed oil, peanut oil, coconut oil, castor oil, flax oil, borage oil, evening primrose oil, marine oils, fish oils, seaweed oils, derived oils oil, oil. mineral, liquid paraffin, petroleum jelly, short chain fatty alcohols, medium chain aliphatic branched fatty alcohols, fatty acid esters with short chain alcohols, isopropyl myristate, isopropyl palmitate, stearate
20 isopropyl, isobutyl adipate, medium chain triglycerides, capric and caprylic triglycerides, Ci ₂ Ci6 octanoates, fatty alcohol ethers, dioctyl ether and / or mixtures thereof.
• 3. NANOCAPSULES, according to claim 1,
25 characterized in that the coating polymer is selected from the group formed by proteins, polysaccharides, polyesters, polyacrylates, polycyanoacrylates, copolymers and / or mixtures thereof.
4. NANOCAPSULES, according to claim 3,
30 characterized in that the coating polymer is selected from the group formed by gelatin, albumin, soy protein, pea protein, broad bean protein, potato protein, wheat protein, whey protein, β
2/8 lactoglobulin, caseinates, zein, alginates, carrageenans, pectins, gum arabic, xanthan gum, guar gum, chitosan, poly (L-lysine), sodium dextran sulfate, carboxymethyl galactomannan, carboxymethyl cellulose, cellulose nitrate, 5 phthalate cellulose acetate, methyl hydroxypropyl cellulose phthalate, hydroxypropyl methyl cellulose succinate, polyvinyl acetate phthalate and mixtures thereof.
5. NANOCAPSULES according to claim 1, characterized in that the ______coat polymer is a • 10 cationic polymer.
6. NANOCAPPSULES, according to claim 5, characterized in that the cationic polymer is selected from the group formed by cationic cellulose derivatives, quaternized hydroxyethyl cellulose, cationic starches,
15 acrylamide and ammonium salt copolymers; quaternized vinylpyrrolidone / vinylimidazole polymers, polyglycols and amines condensation products, polycarbonate polymers and copolymers, polymers called polyquartene-6 merquat, polycarbonate-7, polycarbonate-16,
20 polycarbonate-10, polycarbonate-4 copolymers, dicocoylethylhydroxyethylammonium, graft copolymers with a cellulose skeleton and quaternary ammonium groups; quaternized collagen polypeptides, hydroxypropyl lauryldimone hydrolyzed collagen, quaternized wheat 25 polypeptides, polyethylenimine, cationic silicone polymers, amidomethicone — de — qua. ternium-_22 silicone, adipic acid and copolymers of hydroxypropyl dimethylamine and hydroxypropylamine. dimethyldialylammonium, cationic chitin derivatives,
30 chitosan and its derivatives, condensation products of cationic alkylene dihalogen, condensation products of dibromobutane with bisdialkylamines, bis-dimethylamino-1,3 propane, derivatives of cationic guar gum, guar3 / 8 hydroxypropyltrimony, quaternary ammonium salt polymers, polymers of quaternized polysaccharide of natural derivatives such as azarose, cationic gelatin proteins, cationic gum protein, polyamide cationic polymers 5, cationic polyacrylate polymers, cationic polylactic polymers, cationic polyglycol polymers, cationic polyvinyl polymers, polyaniline polymers. , cationic polymers of polyvinylpyrrolidone, cationic polymers of • 10 amino silicone polymers and copolymers, cationic polymers of polystyrene, cationic polymers of polyvinyl alcohol, cationic polymers of polystyrene and anhydride copolymers of maleic acid, cationic polymers of methyl ether cationic compounds of epoxy resins, cationic polymers of styrene and copolymers of methyl methacrylate, methacrylate, polyacrylates and polymethacrylates of cationic dimethylamino, polyamine derivatives optionally substituted by polyethylene glycol derivatives, polyamine acids under the conditions of pH in which they are the same; Polyethyleneimine; derivatives of quaternized polyvinylpyrrolidone (PVP) and hydrophilic urethane polymers, as well as any mixture of the cationic groups mentioned above.
7. NANOCAPSULES, according to claim 1,
25 characterized in that the hydrophilically active ingredient is selected from the group consisting of —amino acids, peptides, proteins, hydrolyzed proteins, enzymes, hormones, vitamins, minerals, sugars, nucleotides, nucleic acids, molecules and extracts of biological origin and
30 biotechnology, vaccines, synthetic or partially synthetic hydrophilic molecules and / or mixtures thereof.
8. NANOCAPSULES, according to claim 1, characterized in that they comprise other active ingredients
4/8 and / or cosmetic, pharmaceutical and / or food adjuvants. 9. NANOCAPPSULES, according to claim 8, characterized in that the active ingredients and / or adjuvants selected from the group or substances that retain agents that stimulate the curing agents, agents that stimulate agents of re-epithelializing agents, synthesize dermal macromolecules or redensification and / or cosmetics and / or foodstuffs are formed by surfactants, moisture humectants, moisturizers or emollients, curing, re-epithelializing agents, epidermal agents, restructuring firmness agents, cytokine growth factors, agents that act on capillary circulation and / or microcirculation , anti-glycation agents, free radical scavengers and / or anti-atmospheric pollution agents, scavengers of active carbonyl species, 5th reductase inhibiting agents, lysyl and / or prolyl reductase inhibiting agents, defensin synthesis agents, agents bactericidal and / or bacteriostatic agents and / or antimicrobial agents and / or germicidal agents and / or fungicidal agents and / or germ inhibiting agents and / or agents, antiparasitic agents, NO synthase inhibiting agents, kerotolytic agents or agents and / or comedolytic agents, antipsoriasis agents, anti-dandruff agents, anti-inflammatory agents and / or analgesics, - anesthetic agents; - anti-wrinkle-and / or anti-aging agents, antiviral fungistats, histamines, exfoliating peels, deodorants to mask absorbent odor, perfuming agents and / or isolated oils, cosmetic substances for isolated aromatic compounds, agents inhibit permeability vascular, bleaching agents or inhibiting body enzymes and / or antiperspirants, perfumed and / or antioxidation, agents that hydrolytic epidermal enzymes depigmentation of skin, agents that
5/8 sweat degradation, agents that have the ability to filter UV rays, agents that stimulate or regulate keratinocyte differentiation, anti-itch agents, agents that stimulate or inhibit melanin synthesis, pro-pigmentation agents, 5 self-tanning agents, agent of stimulating melanocyte proliferation, liquid propellants, vitamins, amino acids, proteins, biopolymers, gelling polymers, skin relaxing agents, agents that have the ability to reduce or treat bags over the eyes, agents for * 10 treatment and / or sensitive skin care, astringent agents, agents that regulate sebum production, anti-stretch agents, lipolytic agents or agents that stimulate lipolysis, venotonic agents, anti-cellulite agents, soothing agents, agents that act on cellular metabolism, agents to improve the dermal-junction epidermal, agents that induce hair growth or hair loss retardants, agents that inhibit or retard growth ode for hair, heat shock protein synthesis stimulating agents, muscle relaxants, inhibiting agents
20 muscle contraction, agents that inhibit acetylcholine receptor group, cholinergic agents, elastase inhibiting agents, matrix metalloproteinase inhibiting agents, chelating agents, “plant extracts, essential oils, marine extracts, mineral salts, 25 cell extracts, emulsifying agents, agents that stimulate the synthesis of lipids and components ... of the horny layer, ceramides, fatty acids, agents obtained from a process of biofermentation and / or mixtures thereof.
10. NANOCAPSULES, according to claim 9,
30 characterized in that the active ingredients and / or pharmaceutical adjuvants are selected from the group formed by antacids, agents against peptic ulcers and gastroesophageal reflux disease, antispasmodics, analgesics, ξ> / 3 anticholinergic drugs, propulsive drugs, antiemetics, antinusea drugs, agents for biliary therapy, agents for liver therapy, lipotropics, laxatives, antidiarrheals, intestinal adsorbents,
5 anti-propellants, anti-inflammatory drugs, active ingredients against obesity, enzymes, hypoglycemic drugs, insulin and analogues, vitamins, proteins, minerals, anabolic steroids, antithrombotic agents, antifibrinolytics, hemostatic agents, agents • 10 antiarrhythmic agents, cardiac stimulants, cardiac glycosides, vasodilators, antiadrenergic agents, antihypertensive drugs, diuretics, potassium - saving agents, anti - hemorrhoids, anti - aging therapy agents, capillary stabilizing agents, agents that act on the renin - angiotensin system, beta - blockers,. selective calcium channel blockers, non-selective calcium channel blockers, ACE inhibitors, angiotensin II inhibitors, lipid modifying agents, antifungals, healing agents, antipruritics, anti20 histamines, anesthetics, antipsoriatics, chemotherapeutic drugs, corticosteroids, antiseptics, disinfectants, anti-acne agents, products for gynecological use, oxytocics, contraceptives, androgen, estrogen, progestogen, ovulation stimulants,
25 gonadotropins, antiandrogens, products for urological use, antispasmodics, drugs used in benign prostatic hypertrophy, hormones, hormone antagonists, antibiotics, tetracyclines, amphenicols, beta-lactam antibacterials, penicillin, sulfonamides, trimethoprim,
[3]
3 0 macrolides, lincosamides, streptogramins, antibacterial aminoglycosides, antibacterial quinolones, antivirals, immune serum, immunoglobulins, antineoplastic agents, immunomodulatory agents, alkylating agents, antimetabolites,
[4]
7/8 plant alkaloids and other natural products, cytotoxic antibiotics, immunosuppressive agents, drugs for disorders of the skeletal muscle system, antirheumatic agents, muscle relaxants, agents that affect bone structure and mineralization, drugs that act on the nervous system, general anesthetics, anesthetics local, opioids, anti-migraine agents, anticonvulsants, cholinergic agents, dopaminergic agents, antipsychotics, anxiolytics, hypnotics, sedatives, antidepressants, psychostimulants, drugs idem0 antidemence, parasympathomimetics, drugs used in additive disorders, antidepressants, anti-anxiety agents, antipsychotic agents , nasal decongestants, mucolytic agents, cough suppressants, ophthalmic active ingredients, otological agents, anti-glaucoma drugs, miotics, mydriatics, cycloplegics and / or mixtures thereof.
11. PROCESS FOR THE PREPARATION OF NANOCASULES defined in
POLYMERICALLY COATED, as claimed in claim 1, characterized by the fact that it comprises a) preparation of a water-in-oil (w / o) emulsion of an aqueous solution of a hydrophilically active ingredient in liquid oils or lipids, complex microemulsion of the polymer.
12.
FOOD, and b) encapsulation by coacervation of a coating by means of
COSMETICS,
COMPOSITION characterized by_and_l_o_. act as defined in
PHARMACEUTICAL AND / OR comprising nanocapsules, claims 1, 2, 3, 4, 5, 6, 7, 8, 9
13. COMPOSITION, according to which the nanocapsules are solid organic polymer or support selected from the group formed by talc, bentonite, silica, any of the
10.
claim
12, adsorbed on a solid mineral starch or maltodextrin.
[5]
8/8
14. COMPOSITION, according to claim 12, characterized in that this composition is presented in a formulation selected from the group formed by creams, multiple emulsions, anhydrous compositions, aqueous dispersions, oils, 5 milks, balms, foams, lotions, gels, cream gels, hydroalcoholic solutions, hydroglycolic solutions, hydrogels, liniments, serums, soaps, shampoos, conditioners, serum, ointments, mousses, ointments, powders, bars, pencils, vaporizers, aerosols, capsules, gelatin capsules, • 10 soft capsules, hard capsules, tablets, coated sugar tablets, granules, chewing gum, solutions, suspensions, emulsions, syrups, polysaccharide films, jellies and gelatin.
15. COMPOSITION, according to claim 12,
15 characterized in that this composition is incorporated into one. product selected from the group consisting of concealers on the eyes, makeup base, makeup removal lotions, makeup removal milks, eye shadows, lipsticks, glossy lipstick, lip protectors and powders.
16. COMPOSITION, according to claim 12, characterized in that the nanocapsules are incorporated in a tissue fabric, a nonwoven fabric or a medical device.
‘17. USE OF COSMETIC, PHARMACEUTICAL AND / OR COMPOSITION
FOOD, as defined in claim 12, characterized by the fact that it is for the treatment and / or care of the skin, scalp, hair and nails.
18. USE OF THE cosmetic and / or pharmaceutical COMPOSITION, as defined in claim 12, characterized by the fact that it is for the treatment of textile materials.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10758490B2|2020-09-01|Nanocapsules containing microemulsions

---

ES2384060B1|2013-09-23|LIPID NANOPARTICLES CAPSULES.

---

RU2556670C2|2015-07-10|Method of processing fibres and/or textile materials

---

US9717659B2|2017-08-01|Liposomes for the treatment of textile materials

---

JP2019501268A|2019-01-17|Thermoformable dual network hydrogel composition

同族专利:

---

公开号 | 公开日

---

ES2732908T3|2019-11-26|

---

SG188427A1|2013-04-30|

---

MX354840B|2018-03-21|

---

MY166518A|2018-07-05|

---

EP2618926B1|2019-05-08|

---

ES2386177B1|2013-09-23|

---

ES2386177A1|2012-08-10|

---

KR20130138240A|2013-12-18|

---

US20130216596A1|2013-08-22|

---

JP2013537206A|2013-09-30|

---

US10758490B2|2020-09-01|

---

KR101979462B1|2019-05-16|

---

WO2012038061A3|2012-06-07|

---

MX2013003137A|2013-10-17|

---

JP6087282B2|2017-03-01|

---

EP2618926A2|2013-07-31|

---

WO2012038061A2|2012-03-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2800457A|1953-06-30|1957-07-23|Ncr Co|Oil-containing microscopic capsules and method of making them|

---

US3539465A|1968-10-08|1970-11-10|Ncr Co|Encapsulation of hydrophilic liquid-in-oil emulsions|

---

US3692690A|1970-05-27|1972-09-19|Ncr Co|Encapsulation process by complex coacervation using polymers and capsule product therefrom|

---

FR2504535B1|1981-04-28|1987-08-14|Choay Sa|DISACCHARIDES DERIVED FROM URONIC ACID AND GLUCOSAMINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE CONTROL OF BLOOD COAGULATION|

---

GB8519416D0|1985-08-01|1985-09-04|Unilever Plc|Oligosaccharides|

---

GB8630721D0|1986-12-23|1987-02-04|Unilever Plc|Cosmetic compositions|

---

GB8806892D0|1988-03-23|1988-04-27|Unilever Plc|Lactams their synthesis & use in cosmetic compositions|

---

GB8830019D0|1988-12-22|1989-02-15|Unilever Plc|Cosmetic composition|

---

GB8913708D0|1989-06-14|1989-08-02|Unilever Plc|Cosmetic composition|

---

JPH05292899A|1991-06-24|1993-11-09|Ajinomoto Co Inc|Production of microcapsule|

---

US5288502A|1991-10-16|1994-02-22|The University Of Texas System|Preparation and uses of multi-phase microspheres|

---

DE69433723T3|1993-02-22|2008-10-30|Abraxis Bioscience, Inc., Los Angeles|PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM|

---

US5665383A|1993-02-22|1997-09-09|Vivorx Pharmaceuticals, Inc.|Methods for the preparation of immunostimulating agents for in vivo delivery|

---

JPH10131043A|1996-10-30|1998-05-19|Toray Ind Inc|Anti-atopic fiber structure|

---

US6039901A|1997-01-31|2000-03-21|Givaudan Roure Flavors Corporation|Enzymatically protein encapsulating oil particles by complex coacervation|

---

US6916490B1|1998-07-23|2005-07-12|UAB Research Center|Controlled release of bioactive substances|

---

DE10064878A1|2000-12-27|2002-07-04|Cognis Deutschland Gmbh|Encapsulation of emulsions|

---

FR2824756B1|2001-05-16|2005-07-08|Mainelab|MICROCAPSULES BASED ON PLANT PROTEINS|

---

US6720008B2|2002-01-22|2004-04-13|Pr Pharmaceuticals, Inc.|Composition and method for the encapsulation of water-soluble molecules into nanoparticles|

---

JP2004250804A|2003-02-18|2004-09-09|Teijin Fibers Ltd|Sympathetic nerve-activating fabric|

---

CA2581816A1|2004-09-27|2006-04-06|Sigmoid Biotechnologies Limited|Microcapsules comprising a methylxanthine and a corticosteroid|

---

FR2880802B1|2005-01-14|2008-12-19|Sederma Soc Par Actions Simpli|COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT|

---

HU0500379A2|2005-04-12|2007-01-29|Tibor Dr Forster|Phase separation of micellar colloidal solutions|

---

ES2487493T3|2006-03-14|2014-08-21|Neuren Pharmaceuticals Limited|Oral formulations of glycyl-2-methylprolyl glutamate|

---

AU2008231093A1|2007-03-22|2008-10-02|Alkermes, Inc.|Coacervation process|

---

JP2009084224A|2007-09-28|2009-04-23|Fujifilm Corp|Microcapsule and method for producing the same|

---

ES2383271B1|2010-03-24|2013-08-01|Lipotec S.A.|PROCESSING PROCESSING OF FIBERS AND / OR TEXTILE MATERIALS|

---

ES2384060B1|2010-03-24|2013-09-23|Lipotec S.A.|LIPID NANOPARTICLES CAPSULES.|

---

EP2961433A4|2013-02-28|2016-11-30|Univ Ramot|Peptide-based hydrogel particles and uses thereof|BRPI1007711A2|2009-05-04|2016-11-29|Cimtech Pty Ltd|one or more extracts of vigna marina, cocos nucifera l. or terminalia catappa l. for the treatment of wounds, skin disorders and hair loss|

---

US9750777B2|2009-12-10|2017-09-05|Cimtech Pty Limited|Methods and compositions for bone and cartilage repair|

---

US9572880B2|2010-08-27|2017-02-21|Sienna Biopharmaceuticals, Inc.|Ultrasound delivery of nanoparticles|

---

ES2637373T3|2010-08-27|2017-10-13|Sienna Biopharmaceuticals, Inc.|Compositions and methods for directed thermomodulation|

---

MX365818B|2011-11-23|2019-05-30|Therapeuticsmd Inc|Natural combination hormone replacement formulations and therapies.|

---

US20130338122A1|2012-06-18|2013-12-19|Therapeuticsmd, Inc.|Transdermal hormone replacement therapies|

---

US9301920B2|2012-06-18|2016-04-05|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies|

---

US10537581B2|2012-12-21|2020-01-21|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

---

US10806740B2|2012-06-18|2020-10-20|Therapeuticsmd, Inc.|Natural combination hormone replacement formulations and therapies|

---

US20150196640A1|2012-06-18|2015-07-16|Therapeuticsmd, Inc.|Progesterone formulations having a desirable pk profile|

---

US10806697B2|2012-12-21|2020-10-20|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

---

US11246875B2|2012-12-21|2022-02-15|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

---

US11266661B2|2012-12-21|2022-03-08|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

---

US10568891B2|2012-12-21|2020-02-25|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

---

US10471072B2|2012-12-21|2019-11-12|Therapeuticsmd, Inc.|Vaginal inserted estradiol pharmaceutical compositions and methods|

---

WO2014037561A2|2012-09-10|2014-03-13|Laboratorios Cinfa, S.A.|Skin anti-aging composition|

---

ES2629903T3|2012-10-11|2017-08-16|Nanocomposix, Inc.|Compositions and method of silver nanoplates|

---

ES2481940B1|2012-12-17|2015-05-06|Universidade De Santiago De Compostela|Proteamine Nanocapsules|

---

US9180091B2|2012-12-21|2015-11-10|Therapeuticsmd, Inc.|Soluble estradiol capsule for vaginal insertion|

---

KR102267689B1|2013-03-15|2021-06-22|마리 케이 인코포레이티드|Cosmetic compositions and uses thereof|

---

TW201532621A|2013-04-22|2015-09-01|Neocutis Sa|Antioxidant compositions and methods of using the same|

---

EP2821077A1|2013-07-04|2015-01-07|Praxis Biopharma Research Institute|Lipid nanoparticles for wound healing|

---

JP6543258B2|2013-09-16|2019-07-10|アストラゼネカ アクチボラグ|Therapeutic polymerizable nanoparticles and methods of making and using the same|

---

US20150099680A1|2013-10-04|2015-04-09|The Procter & Gamble Company|Benefit agent containing delivery particle|

---

JP6533232B2|2014-01-27|2019-06-19|イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ．|Nanoencapsulation of hydrophilic active compounds|

---

CN106793784A|2014-03-10|2017-05-31|纽约市哥伦比亚大学理事会|Vegetalitas antimicrobial compositions|

---

RU2569734C2|2014-03-31|2015-11-27|Александр Александрович Кролевец|Method of producing nanocapsules of resveratrol in sodium alginate|

---

US20150290120A1|2014-04-10|2015-10-15|Cgtn C.V.|Skin care composition comprising plant extracts|

---

DE102014208440B4|2014-05-06|2018-09-27|Beiersdorf Ag|Formulations with an outer gel phase and an inner particulate phase containing stabilized oxidation- and / or UV-sensitive agents|

---

RU2578403C2|2014-05-12|2016-03-27|Александр Александрович Кролевец|Method of producing nanocapsules of cytokinins|

---

JP2017516768A|2014-05-22|2017-06-22|セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ．|Natural combination hormone replacement therapy and therapy|

---

CN104027776A|2014-06-25|2014-09-10|济南伟传信息技术有限公司|Traditional Chinese medicine for treating bromhidrosis|

---

KR102325943B1|2014-08-07|2021-11-12|주환바이오.셀|Composition having improved light stability of peanut sprout extract|

---

KR101671580B1|2014-08-26|2016-11-02|영남대학교 산학협력단|Preparation method of minoxidil solution|

---

CN105708748B|2014-12-04|2020-06-30|玫琳凯有限公司|Cosmetic composition|

---

FR3031301B1|2015-01-05|2019-05-03|Jean-Noel Thorel|NOVEL COMPOSITION COMPRISING CHROMIUM AND TYROSINE DERIVATIVES FOR THE TREATMENT OF SKIN|

---

RU2595834C1|2015-04-14|2016-08-27|Александр Александрович Кролевец|Method of producing nanocapsules of green tea extract|

---

US10328087B2|2015-07-23|2019-06-25|Therapeuticsmd, Inc.|Formulations for solubilizing hormones|

---

CN108024947A|2015-07-27|2018-05-11|玫琳凯有限公司|Topical skin preparations|

---

EP3328354A4|2015-07-28|2019-03-20|Mary Kay, Inc.|Topical skin formulations|

---

BE1023579B1|2015-11-05|2017-05-09|LOëN HOLDING S.A.R.L.|REPULSIVE ACCESSORIES AGAINST CHIPS, MITES AND INSECTS|

---

BE1023575B1|2015-11-05|2017-05-08|LOëN HOLDING S.A.R.L.|SOLID GALENIC|

---

PT108994A|2015-11-30|2017-05-30|Cofac - Coop De Formação E Animação Cultural|GOLD NANOSYSTEM WITH BIOPOLIMERIC COATING AND ABSORPTION RANGE IN THE NEXT INFRARED AND METHOD FOR THEIR PREPARATION|

---

LU92908B1|2015-12-15|2017-06-19|Uption Sarl|Extract from the vine as an active ingredient able to stabilize the oil / water interfaces|

---

RU2631883C2|2015-12-31|2017-09-28|Александр Александрович Кролевец|Method for production of nanocapules of penicillin group medicine preparations in konjac gum|

---

EP3435977A4|2016-04-01|2019-10-16|Therapeuticsmd, Inc.|Steroid hormone pharmaceutical composition|

---

US10286077B2|2016-04-01|2019-05-14|Therapeuticsmd, Inc.|Steroid hormone compositions in medium chain oils|

---

KR102354954B1|2016-04-04|2022-01-24|오메자 엘엘씨|Fish Oil Topical Composition|

---

US10493020B2|2016-04-14|2019-12-03|The Procter & Gamble Company|Method of improving the appearance of periorbital dyschromia|

---

RU2650966C1|2016-10-20|2018-04-18|Александр Александрович Кролевец|Method for obtaining nanocapules of spirulina in carrageenan|

---

IT201600106992A1|2016-10-24|2018-04-24|General Services Spain Italy Sl|Composition comprising microstructures for the controlled release of ozonated oil.|

---

KR101869918B1|2016-11-30|2018-07-20|김성재|Soap composition for relieving the symptoms of atopic dermatitis|

---

WO2018170355A1|2017-03-17|2018-09-20|Mary Kay Inc.|Cosmetic compositions and methods|

---

KR101932687B1|2017-03-28|2019-04-08|주식회사 케이피티|Composition for Lipgloss, Method of Preparation there of|

---

US9943503B1|2017-10-19|2018-04-17|Edward Wick|Pharmaceutical composition for treating bacterial and viral infections|

---

US10166265B1|2018-02-09|2019-01-01|Edward Wick|Pharmaceutical composition for treating bacterial and viral infections|

---

US10054548B1|2017-11-02|2018-08-21|King Saud University|PH sensing biofilm|

---

GB201807801D0|2018-05-14|2018-06-27|Plantine Holdings Ltd|Microparticles|

---

KR101964666B1|2018-07-24|2019-04-02|주식회사 루치온|Water-soluble solid foam cleanser|

---

CN109225162B|2018-11-09|2022-03-01|华东理工大学|Preparation method of aspartic acid modified walnut shell adsorbent|

---

KR102154565B1|2018-11-13|2020-09-10|한국화학연구원|Microcapsule containing natural oil and method for preparing thereof|

---

KR102331844B1|2018-11-28|2021-11-29|주식회사 올댓네이쳐|Adhesive composition for sunblock comprising mixture of chitosan, gluten and gellatin as effective component and uses thereof|

---

US11253467B2|2018-12-03|2022-02-22|Slc Skin Llc.|Wrinkle treatment|

---

CN109645499A|2018-12-27|2019-04-19|中国农业科学院农产品加工研究所|Shelter the preparation method of the complex coacervation entrapment systems of food-borne active peptide bitter taste|

---

KR102261590B1|2019-01-11|2021-06-07|한국콜마주식회사|Cosmetic Composition Containing Capsule absorbed Water Soluble Extraction|

---

WO2020149684A2|2019-01-18|2020-07-23|주식회사 대하맨텍|Biodegradable capsule with safety due to no irritation to human body and manufacturing method therefor|

---

KR102272566B1|2019-01-18|2021-07-05|주식회사 대하맨텍|Biodegradable capsule without irritation to human body and manufacturing method of the same|

---

WO2020208642A1|2019-04-11|2020-10-15|Technion Research & Development Foundation Limited|Formulations for encapsulation and bioavailability improvement of bioactive compounds based on natural plant based materials|

---

CN110433741B|2019-07-08|2022-01-14|浙江工业大学|Aromatic antibacterial microcapsule with carbon skeleton and preparation method thereof|

---

CN110301649A|2019-08-09|2019-10-08|湖南康琪壹佰生物科技有限公司|A kind of collagen tripeptide compound and preparation method thereof with anti-aging effects|

---

CN110585054A|2019-08-21|2019-12-20|广州市暨达生物科技有限公司|Composition for skin repair|

---

TR201913215A2|2019-09-02|2021-03-22|Univ Yeditepe|USE OF HERBAL EXOSOMES TO INCREASE THE VITALITY OF SKIN CELLS AND THEIR HAIR REMOVAL CAPACITY|

---

KR102263367B1|2019-11-11|2021-06-10|동방비앤에이치|fabric conditioner composite comprising citric acid, and manufacturing apparatus thereof|

---

CN111110845A|2020-01-21|2020-05-08|邢更彦|Novel shock wave treatment coupling agent with anti-inflammatory and analgesic effects and preparation method thereof|

---

KR102331896B1|2020-01-21|2021-11-25|한남대학교 산학협력단|Flame retardant microcapsule and preparation method thereof|

---

KR102324171B1|2020-02-28|2021-11-09|전남대학교산학협력단|Double-hydrophobic-coating through quenching for hydrogels and its manufacturing method|

---

WO2022013233A1|2020-07-15|2022-01-20|Xbrane Biopharma Ab|Water-free process for preparing a pharmaceutical composition for a more sustained and controlled release of triptorelin or a salt thereof|

---

CN113018504A|2021-03-11|2021-06-25|华沃生物科技有限公司|Anti-allergic nasal liquid dressing and preparation method thereof|

法律状态:
2020-06-09| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-07-21| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-02-17| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-05-18| B07G| Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]|

---

2021-10-19| B350| Update of information on the portal [chapter 15.35 patent gazette]|

---

2021-11-03| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

ES201031400A|ES2386177B1|2010-09-21|2010-09-21|NANOCAPSULES CONTAINING MICROEMULSIONS|

---

ESP201031400|2010-09-21|

---

PCT/EP2011/004700|WO2012038061A2|2010-09-21|2011-09-20|Nanocapsules containing microemulsions|

---